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Abstract
Introduction: Lack of study publication leads to bias in the scientific literature. It is
important to better understand this phenomenon and find methods for mitigation.
Research Question: How many clinical trials registered on ClinicalTrials.gov in London,
Ontario are started, completed, and published?
Methods: Data from all studies in the ClinicalTrials.gov registry associated with London,
Ontario were collected, from registry conception until the end of 2017. We determined
whether these registered studies were published by July 2020 and whether their first
publication included their planned primary outcome at all. Main factors associated with
non-publication were assessed using multivariable log-binomial regression. Multivariable
modified Poisson regression was used to assess the association between enrollment size
and publication. Time to publication was assessed using multiple linear regression.
Results: Of the registered studies (n = 2446), only 38% were published and 30% with
their planned primary outcome. Median time to publication post-start was 53 months
[IQR: 36, 75]. Factors associated with publication were randomized design, prospective
registration, industry funding, drug study, and enrollment size (p < 0.05). Factors
associated with shorter time to publication were positive results, prospective registration,
and industry funding, while drug studies were associated with longer time to publication
(p < 0.05). Surgical studies seemed to have decreased chances of publication and
lengthened time to publication but was not statistically significant in either case.
Conclusions: A substantial proportion of clinical trials from London, Ontario remained
unpublished. The factors predictive of non-publication and time to publication suggest
potential avenues for increasing publication rates.

Keywords
Publication bias, selective outcome reporting, time to publication, clinical trial
registration, ClinicalTrials.gov, research integrity
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Summary for Lay Audience
An inherent limitation of scientific literature is that we only know the information
that is publicly accessible through publications. Having as much information as possible
is important when making decisions, especially when it comes to treating life-threatening
illnesses. When studies are not published, the amount of information available is reduced.
Even worse is when certain factors make studies less likely to be published, such
as unfavourable results or the type of treatments studied. Publication bias occurs when
the amount of information available is skewed because some studies are less likely to be
published than others. Additionally, there may be selective outcome reporting, where
some studies are published with only a subset of their results. These issues are highly
prevalent and hinder our ability to make reliable scientific decisions. Unfortunately, there
is no way of knowing about every single study that ever existed. The closest thing we
have are study registries like ClinicalTrials.gov, where studies are ideally registered
before they are conducted or published.
The purpose of our study was to look at registered trials affiliated with London,
Ontario, Canada to determine what proportion of these registered studies were ultimately
published and to determine factors that may predict a study not being published. We
found that fewer than 40% of these studies were published, which suggests that the
published literature affiliated with London, Ontario represents fewer than half of all of its
registered studies. We were able to quantify several factors associated with publication
that could be addressed to increase publication rates in the future.
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Preface
The main topics of our project were publication and outcome reporting bias. Our goal
was to better characterize and address these phenomena within the context of studies
conducted in London, Ontario over the past 20 years. This paper aims to provide the
justification for our project, the methodology used, and the results of our work. Our hope
is that this project can serve as the foundation for further research and development in
this area in order to improve research integrity and transparency.
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Chapter 1

1

Introduction

Publication bias is an umbrella term for the impact of factors on publishing study results.
However, the context and implications of this may not be well understood. This first
chapter aims to provide an overview of the relevant concepts, the philosophical basis for
preventing publication bias, and the current state of scientific research.

1.1 Key Concepts
Publication bias is defined as when “published literature is systematically
unrepresentative of the population of completed studies” (Rothstein et al., 2006). In
simpler terms, it is the failure to publish the results of a study due to internal or external
factors (DeVito & Goldacre, 2019). This limits the readily available information in the
scientific literature and can cripple the clinical decision-making of those that rely on that
information (Chan et al., 2008). With as many as half of all clinical studies remaining
unpublished (Song et al., 2010), it is imperative that we better understand publication bias
to mitigate its adverse impacts. Although this issue is not limited to clinical interventions
or specific study types, clinical studies will be the focus of this paper.
“Publication” refers to the public release of the results of a study in the form of a formal
study report, which can include but is not limited to a manuscript, report, or conference
abstract. They can be published in scientific journals (Blümle et al., 2014), conference
proceedings, and other online platforms (Ganga & Edupuganti, 2017). Since it would be
infeasible to identify every study that may have ever been conceptualized or conducted,
metaresearchers rely on existing databases that record information on studies before they
are conducted or published, such as public registries, ethics review submissions (Blümle
et al., 2014), and clinical study repositories (Doshi et al., 2013). “Bias” implies a
systematic skew in a certain direction due to an identifiable cause, which differentiates it
from non-publication alone in that the latter looks at failure to publish without an inherent
focus on why (Al-Durra et al., 2018; Jones et al., 2013). Studies of publication biases aim
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to assess the factors associated with the non-publication of studies, which may include
the direction and strength of the results (Dickersin & Min, 1993).
Outcome reporting bias is a subset of publication bias in that it is the non-publication of
certain results within a given study (Dwan et al., 2008; Goldacre et al., 2019). That is,
certain outcomes assessed in a study may be present in a publication while others are
omitted or demoted to less important objectives. The potential causes of selective
outcome reporting may be similar to those of publication bias as a whole (Song et al.,
2010). However, it can be harder to detect because the selectively omitted results would
not be obvious from the publication alone. One would have to obtain prior information on
the planned outcomes for a given study, which may not be readily available, and compare
them to the published outcomes to find such discrepancies (Dwan et al., 2008; Goldacre
et al., 2019). To that end, registries can protect against selective reporting as studies must
register their outcomes of interest and report any changes over the course of the study.
This increases transparency, as any discrepancies would become apparent when
comparing registry data to corresponding publications. Nevertheless, selective outcome
reporting can lead to bias in the published literature and may be considered just as
detrimental as the non-publication of entire studies, while being potentially more elusive.

1.2 Ethics of Publication Bias
Strech (2012) argues that the prevention of publication bias is an ethical obligation
because it prevents potentially valuable information from being accessible. Not only does
this skew the published literature, but the inclusion of unpublished results also has the
potential to change the consensus on the effectiveness of treatments (Turner et al., 2008).
The misrepresentation of treatment effects that results from keeping results unpublished
can harm patients, waste valuable resources, and inadvertently exploit study participants
(Strech, 2012).
The most obvious consequences of publication bias are the negative effects on patient
health, especially if related to the nature of the study results. Published studies tend to
report larger effect sizes and overestimate the benefits of a given treatment compared to
unpublished studies (Moreno et al., 2009; Song et al., 2010). Published literature also
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tends to underestimate harms (Dickersin & Chalmers, 2011) while unpublished literature
provides much more information on adverse effects (Wieseler et al., 2013). Indeed,
Turner et al. (2008) found that the inclusion of unpublished literature could dramatically
shift or even reverse the original outlook. In their systematic review of various
antidepressant trials approved by the Food and Drug Administration (FDA), they found
that the overwhelming majority of resulting publications were positive. However,
including unpublished FDA reports revealed almost as many negative results as positive,
which seriously called into question the effectiveness of these antidepressants (Turner et
al., 2008). These findings demonstrated that the published literature can fail to adequately
encapsulate all the relevant data for a given treatment and can be heavily skewed.
Another issue is that publication bias contributes to the improper allocation of resources.
A substantial amount of time and funding goes into conducting research so if the results
of that work are not published, that money and effort goes to waste. Strand et al. (2017)
estimates that roughly 50% of research funding goes into studies that remain
unpublished. With an estimated 85% of research funding going to waste overall
(Chalmers & Glasziou, 2009), non-publication is a waste of resources that should not be
overlooked. Even poorly conducted or negative studies are beneficial when published
because they can reduce redundant research and prevent other researchers from
committing the same methodological errors (DeVito & Goldacre, 2019; Doshi et al.,
2013; Song et al., 2010). Withholding data can also lead to ineffective or even dangerous
medicines being purchased and funded, potentially wasting billions of dollars a year
(Juni, 2002; Thaler et al., 2015). Therefore, failing to publish results is unethical and
wastes limited resources that could have been used elsewhere.
Not publishing results is also an injustice to the people who agreed to participate in the
trial. Research participants consent to give their time and energy towards a study, while
often giving up their privacy, with the expectation that the results will benefit the rest of
society if not themselves (Jones et al., 2013). Clinical interventions also pose some risk to
the participants due to potential adverse effects and the forgoing of potentially better
alternative treatments (Jones et al., 2013). Unfortunately, a large amount of patient data
never sees the light of day (Jones et al., 2013; Kirkham et al., 2016). Failing to publish
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this data is exploitative because it puts patients at risk and wastes their efforts while
giving nothing back. Furthermore, researchers and participants alike may not know their
study is redundant if past research is not published, which would needlessly put even
more participants at risk. To put this into perspective, a meta-analysis of intravenous
streptokinase trials prior to 1973 (inclusive) found that it significantly reduced mortality
from acute infarctions. Even though adequate data already existed, 25 subsequent trials
were conducted from 1973 to 1988, enrolling almost 35,000 additional patients (Lau et
al., 2010). These subsequent trials were mostly redundant and likely deprived thousands
of control patients from an already proven treatment.

1.3 Real-World Implications
An important example of the patient harm that can result from publication bias is the
formerly FDA-approved rosiglitazone, a drug developed by GlaxoSmithKline (GSK) to
reduce blood sugar in people with diabetes. It was speculated that the original approval in
1999 was based on limited publicly available data that was not adequately powered for
cardiovascular events (Nissen & Wolski, 2007). After including both new and
unpublished data from the FDA and GSK registries in their meta-analysis, Nissen &
Wolski (2007) found that rosiglitazone significantly increased the odds of myocardial
infarction by 43% (odds ratio [OR] 1.43 [95% confidence interval [CI]: 1.03, 1.98])
compared to alternative diabetic treatments. The increased risk of cardiovascular events
eventually led the FDA to restrict this drug in September 2010 (FDA, 2018), but not
before being used for over a decade. It is estimated to have caused 431 deaths for every
100,000 patients compared to safer alternatives (Loke et al., 2011), as well as 6000 to
8000 additional myocardial infarctions among US and UK patients in 2010 alone (Chan
et al., 2014). Had the unpublished data been publicly available beforehand, the use of
rosiglitazone in lieu of safer alternatives could have been prevented.
While outcome reporting bias may be more nuanced, its implications are no less
important. One such case was celecoxib, an FDA-approved non-steroidal antiinflammatory drug (NSAID) for treatment of arthritis. Both the drug trial and subsequent
publication were funded by its manufacturer, Pharmacia (Juni, 2002; Silverstein et al.,
2000). In their CLASS trial publication, Silverstein et al. (2000) originally concluded that
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celecoxib significantly reduced annual incidence of gastrointestinal ulcer complications
compared to other NSAIDs (0.44% vs. 1.27%, p = 0.04) during 6 months of treatment.
What they neglected to mention was that the trial actually lasted 12 to 15 months. In fact,
15-month follow-up data from FDA reports showed it was barely better than the
comparator ibuprofen (22.4% vs. 23%) (McCormack & Rangno, 2002). Furthermore, the
majority of ulcer complications in the latter half of the study were from the celecoxib
group (Juni, 2002). This supports that celecoxib does not actually cause fewer adverse
effects compared to conventional NSAIDs, only delayed. Unfortunately, the omission of
the 12- and 15-month data from the original publication led to a misleading perception of
celecoxib as being safer. Despite its failure to demonstrate superiority long-term, it had
over 14 million prescriptions in 2004 from the US alone, instead of cheaper alternatives
(Chan et al., 2014). Even when studies are published, the selective reporting of results
can overestimate treatment benefits and warp our perception of them.

1.4 Shortcomings of Research Infrastructure
For the purposes of our project, we used the ClinicalTrials.gov registry as our reference
for planned clinical trials, which was created by the Food and Drug Administration
Modernization Act (FDAMA) in 1997 and was made available to the public in 2000
(NLM, n.d.). The act required that all clinical trials in the United States of America be
registered in the database at least before publication (Viteri-García et al., 2018),
providing an effective record of virtually all planned clinical trials in the US. The later
Food and Drug Administration Amendments Act (FDAAA) of 2007 required that clinical
trials also report their results within one year of completion (Prayle et al., 2012).
Additionally, the International Committee of Medical Journal Editors (ICMJE) began
requiring prospective trial registration for journal publications in 2005 (De Angelis et al.,
2004), which likely further encouraged researchers to register worldwide.
While Health Canada encourages trial sponsors to register in public registries like
ClinicalTrials.gov (Canada.ca, 2016) and it remains a popular option among Canadian
institutions, registration is not legally required as it is in the US (ClinRegs, 2021). This
may limit the scope of the registry with regard to studies from Canadian research
institutions. Indeed, many have called for Health Canada to match the FDA on this
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particular legal requirement (Shuchman, 2013). Nevertheless, ClinicalTrials.gov remains
a feasible and useful source of data on Canadian studies as Health Canada does not
provide a comprehensive and comparable alternative (Canada.ca, 2016).
While one may assume that legally mandating registration and reporting results may
increase accountability, some findings suggest that may not be the case. Although
prospective registration should substantially decrease reporting bias in theory, Thaler et
al. (2015) found it was not effective in preventing outcome discrepancies. Even more
worrisome is that legal requirements themselves are not useful if they are not enforced.
Despite the threat of fines by the FDA, Prayle et al. (2012) found that 78% of clinical
trials still failed to report their results within one year of completion. To further shed light
on this non-compliance, DeVito et al. (2018) developed the online FDAAA
TrialsTracker, which tracks registered studies on ClinicalTrials.gov and records whether
they have reported their results after study completion. To date, the tracker has revealed a
substantial number of unreported results and unenforced fines. However, one of the
drawbacks of such a generalized tool is that it is severely limited in depth. Taken at face
value, a search of the prominent research institutions based in London, Ontario (i.e.,
Western University and Lawson Health Research Institute) would suggest that 80% of
their clinical trials fail to report their results (as of July 31, 2020). While this may seem
like a staggering proportion, the reality is that the tracker only found a total of five
completed studies from those institutions (EBM DataLab, 2018), which seems
implausible and makes the estimate largely unreliable. Although the tracker is useful for
providing broad general statistics, its use in addressing specific regions is limited. This
highlights the continued need for in-depth research on publication that is smaller in scope
to allow for greater focus.
Even if study results are submitted to the FDA, they are not readily accessible in the
scientific literature, let alone to the general public. Lack of time and interest remain
commonly cited personal reasons among researchers for failing to publish (Timmer et al.,
2002). That being the case, a potential remedy would be for study data to be published by
other willing researchers. This is what the Restoring Invisible and Abandoned Trials
(RIAT) initiative attempts to achieve, by publishing the results of previously unpublished
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industry clinical study reports on behalf of the original researchers (Doshi et al., 2013).
These reports are rarely freely accessible and may only be granted upon request to the
companies or their investigators (Chan et al., 2014). Thus, the RIAT initiative aims to
both increase the availability of such data and expose the vast registry of industry trials
that would have otherwise remained hidden. Although the necessity is clear, it remains to
be seen if such practises will become commonplace.
A potential misconception regarding failure to publish is that it is due to rejection by
scientific journals. On the contrary, negative or non-significant results do not seem to
prevent eventual journal acceptance (Song et al., 2010). In fact, Timmer et al. (2002)
estimates that 76% of unpublished studies were never submitted to journals in the first
place. Among the remaining that were rejected, half were due to improper methodology
or uninteresting topics. Even the few studies that were initially rejected due to negative
results eventually reached publication in other journals (Timmer et al., 2002).
Furthermore, several journals exist that actively publish negative findings (Amsen, 2015;
Horsley et al., 2015). Thus, it is clear that the main predictors of non-publication occur
well before attempting to submit the write-up and cannot be solely attributed to the
journals (Song et al., 2010; Thaler et al., 2015).
However, that is not to say that the current framework is without fault. While the
Consolidated Standards of Reporting Trials (CONSORT) statement offers a standard for
publication manuscripts to follow, journals are not forced to follow it (Goldacre et al.,
2019) and many other areas lack such rigorous guidelines. Among systematic reviews,
Potthast et al. (2014) found that almost 90% failed to include industry registries,
suggesting inadequate methodology for including grey and unpublished literature.
Sources that document the planning of a study, such as registries, protocols, and ethics
review databases, often lack consistency and detail (Chan et al., 2014). In particular,
public registry entries are often limited and contain far less information on study
outcomes than clinical study reports from industry trials (Dwan et al., 2008; Wieseler et
al., 2013). Even if one has access to these reports, they are notoriously long and difficult
to navigate, with some spanning over 600 pages (Doshi & Jefferson, 2013). The lack of
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standard guidelines in these crucial areas reduces the feasibility of these data sources,
especially when it comes to detecting non-publication and outcome discrepancies.

1.5 Summary
Publication bias and selective outcome reporting skew the published literature and
prevent an accurate representation of treatment outcomes. Non-publication is unethical
because it wastes resources and can lead to patient harm, whether by impairing clinical
decision-making or needlessly putting patients at risk. Regulations mandating publication
are not sufficiently enforced and there lacks rigorous guidelines for grey literature.
Fortunately, registries provide a useful tool for detecting non-publication and outcome
discrepancies. However, that alone may not be enough to understand the nuances of
publication bias and how to prevent it.
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Chapter 2

2

Literature Review

Before beginning our study, we conducted a review of the relevant literature to assess
what has already been done and inform our methodology. The following chapter will
outline our review strategy and discuss our findings. Our focus was on publication bias,
outcome reporting bias, and potential risk factors. A few studies had data on time to
publication, which were included as well.

2.1 Review Methodology
The main topic of our review was the proportion of baseline studies that reached
publication and what characteristics were associated with them. Any measures of
discrepancies between planned and published outcomes, as well as time to publication
analysis, were also reviewed if included in the publication. The purpose of our review
was to explore the existing literature for relevant study data and methodology. This
would give us a reference for our publication statistics as well as suggestions for potential
covariates in our regression models. We also assessed the existing methodology for
potential weaknesses that could be addressed in our study.
Following an exploratory search, a list of key terms was developed to represent our topic
of interest: publication bias, outcome reporting bias, registries, ethics submissions,
protocols, and RCTs. These terms were used to develop our systematic search strategy in
the Ovid search engine (Wolters Kluwer, n.d.), which was then tailored to each of our
intended databases of published medical literature: Medline and Embase. We completed
the search on October 16, 2019, yielding a total of 1007 results after removing duplicates.
(Appendix A)
We were interested in primary studies that compared pre-study documentation (i.e.,
registries, protocols, etc.) to corresponding publications of medical intervention RCTs.
Studies that did not collect primary data or that did not analyze both components of this
comparison together were not included. Published manuscripts, journal articles, and

10

abstracts were included. Review articles, presentations, and letters or editorials were
excluded. Protocols were also excluded unless they included preliminary or final results.
A single reviewer (A. B.) conducted two stages of screening, using Mendeley to manage
citations. In the first stage, the publication abstracts were reviewed for key terms, and
clearly irrelevant results were excluded. Manual forward and backward citation
searching, of included articles that strongly matched our key terms, was then conducted
to find additional papers that may have been relevant. In the second stage, publication
abstracts were reviewed for our inclusion criteria and those that met them were added to
our final inclusion group. In cases where the abstract alone was inconclusive, the full text
was reviewed. Screening was completed on December 14, 2019.
For our literature review, the full text of each of our final included studies was reviewed
for relevant results. Data on publication rates, prevalence of selective outcome reporting,
and time to publication intervals were extracted. Publication measures were converted to
proportion published and time to publication measures were recorded as months. The
statistical significance and direction of any comparative statistics for potential predictors
of publication and time to publication were recorded. Acceptable comparative statistics
included odds ratios (OR), relative risk (RR), hazard ratios (HR), and absolute
differences. If these statistics were not present but the relevant data was available, they
were manually calculated. Data sources and sample sizes were also recorded. Table 1 and
Table 2 present an overview of our findings for publication and time to publication,
respectively. Due to lack of consistency in outcome discrepancy analyses, they were not
included in these tables and will instead be addressed in text.
Although the measures of proportion published and time to publication should
theoretically have been comparable, we decided it was not reasonable to combine them
via meta-analysis because the underlying studies differed greatly in inclusion criteria and
baseline data sources. While the pre-existing results can serve as reference, they may not
directly inform future studies in other contexts.
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2.2 Types of Studies
A total of 15 primary studies were included in our literature review, which had a variety
of retrospective data sources being used as their baseline reference for assessing
publication bias (Table 1). Although their sources varied, each study followed an
analogous structure; a pre-existing catalogue of planned or completed studies was used to
form a retrospective cohort, followed by a search for corresponding publications.
Five of our included studies used public registries as their baseline, specifically
ClinicalTrials.gov (Al-Durra et al., 2018; Chahal et al., 2012; Jones et al., 2013; Khan et
al., 2014; Pica & Bourgeois, 2016). Seven of them looked at protocol submissions to
various ethics review boards (Blümle et al., 2008; Blümle et al., 2014; Kasenda et al.,
2014; Kirkham et al., 2016; Menzel et al., 2007; Rosenthal et al., 2015; von Elm et al.,
2008). Two studies delved into industry registries, specifically that of GSK (Pang &
Loke, 2011; Tfelt-Hansen, 2009). One analyzed government-funded studies, specifically
those funded by the National Institutes of Health (NIH) (Dickersin & Min, 1993).

2.3 Proportion Published
None of the studies included in our literature review reported that 100% of their baseline
studies were published, suggesting study loss is broadly prevalent in the scientific
literature. Proportion published ranged from virtually none to almost all of their
respective cohorts. These extremes likely represent vastly different methodology and
timing. Dickersin & Min (1993) reported 93% of their cohort of studies was published.
However, their analysis of NIH-funded studies had a publication window of over 9 years,
allowing substantially more time for studies to reach publication than other similar
studies, and excluded discontinued trials. In contrast, Tfelt-Hansen (2009) found that
virtually none of their industry registry studies were published. While industry studies
may indeed have questionable rates of publication (Doshi et al., 2013), a likely alternative
explanation in this case would be the sample size of only six manually-found studies.
Publication bias studies with large sample sizes and unrestrictive inclusion criteria (i.e.,
public registries and ethics submissions) tended to report fairly similar results to one
another, ranging from 50% to 70% eventually being published (Table 1). While still a
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wide range, we can roughly estimate from the existing literature that over half of all
medical RCTs are published in some form. More restrictive data sources (i.e., industry
registries) had comparatively lower rates of publication (Pang & Loke, 2011; TfeltHansen, 2009).
Notably, Al-Durra et al. (2018) used a unique method of calculating proportion published
by only including published studies that reported their registered primary outcomes. This
created a hybrid measure that incorporated elements of both non-publication and
selective outcome reporting, as opposed to the conventional overall proportion published.
One could argue that such a measure is more effective at characterizing research loss, as
published studies may not report all of their ascertained results.
The most common reason given for failure to publish was lack of time or interest, which
made up 43% of responses (Dickersin & Min, 1993). Dickersin & Min (1993) found that
an additional 38% of unpublished studies had general operational problems, which
coincided with the 40% of discontinued studies citing poor recruitment reported by
Kasenda et al. (2014). Incomplete analysis made up the remainder of the reasons
(14.3%), with the rest being unknown (5.4%) (Dickersin & Min, 1993).

2.4 Selective Outcome Reporting
Among the publication studies that assessed outcome discrepancies, prevalence of
selective outcome reporting was found to be widespread. Perhaps due to its nuanced
nature, a variety of different classifications were used to characterize its prevalence.
These classifications were generally not uniform across studies.
Overall, 29–35% of registered studies had a discrepancy in their primary outcomes
(Chahal et al., 2012; Pang & Loke, 2011), while 64% had a discrepancy in their
secondary outcomes (Pang & Loke, 2011) and as high as 80% had at least one
discrepancy in either (Chahal et al., 2012). Al-Durra et al. (2018) estimated that of
published trials, only 2% outright did not report their primary outcomes at all. This
suggests that the vast majority of published studies report their primary outcomes in some
form, even if not as the originally intended primary outcome. However, Blümle et al.
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(2008) estimated that 43% of trial protocols fail to prespecify a primary outcome at all.
This makes assessing discrepancies challenging in such cases and may reflect a lack of
rigorous oversight in protocol submissions.
Some studies focussed on the publication of prespecified outcomes themselves. Kirkham
et al. (2016) found that only 70% of all planned outcomes from published trials are
published in full. When looking at patient outcomes, this dropped to 43%. Industry
funding seemed to coincide with a decreased likelihood of fully reporting all outcomes,
though not significantly (RR 0.64 [95% CI: 0.30, 1.38]) (Kirkham et al., 2016). Likewise,
Pang & Loke (2011) found that industry trials tended to underreport outcomes related to
treatment side effects, with 88% of all adverse effects going unreported. Furthermore,
93% of “serious” and 85% of “fatal” side effects were not reported in publications (Pang
& Loke, 2011). This is especially worrisome when “harm” outcomes should actually
increase odds of publication compared to efficacy outcomes (OR 3.57 [1.09, 11.11]), at
least for surgical studies (Rosenthal et al., 2015). Whether the lack of full reporting
reflects differing tendencies between types of interventions or a systemic problem among
industry-conducted trials remains uncertain.

2.5 Time to Publication Interval
For studies registered on ClinicalTrials.gov, median time to publication following study
completion ranged from 27 to 38 months (Jones et al., 2013; Khan et al., 2014). Jones et
al. (2013) found the proportion published to be highest between 24 and 48 months,
followed by a plateau thereafter. Al-Durra et al. (2018) also found that about half of their
studies were published within 48–72 months. Pica & Bourgeois (2016) reported a mean
of 29 months following primary completion. Overall, existing analyses suggest that about
half of all studies are published within 4 years following conception and within 2–3 years
following completion.
Unpublished trials that posted results to ClinicalTrials.gov did so after a median time of
22 months post-completion (Jones et al., 2013). For ethics submissions, Menzel et al.
(2007) measured time to publication from the date of approval and reported a median
time of 46 months. In addition, Khan et al. (2014) found that studies that published post-
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2006 tended to do so sooner than those that published in 2005 and earlier, suggesting that
time to publication may be decreasing over time.

2.6 Characteristics Associated With Publication
Registering or submitting a protocol prior to conducting a study is intended to increase
transparency and encourage researchers to adhere to prespecified study plans. Having a
prior record can hold researchers accountable for changes to the methodology made after
the study has begun. Despite this reasoning, prospective registration was not significantly
associated with increased publication in the existing literature. In fact, Al-Durra et al.
(2018) and Khan et al. (2014) found that prospective registration may coincide with a
decrease in odds of publication, though not statistically significant (OR 0.75 [0.44, 1.28]
and 0.4 [0.1, 1.0], respectively). Prospective registration was also not significantly
associated with time to publication (HR 1.2 [0.8, 1.8]) (Khan et al., 2014).
Funding source was one of the most commonly studied and controversial predictors.
Industry sponsors may affect the conduct of a trial, even though the true extent of their
influence is often omitted from the publication (Lundh et al., 2012). In fact, some
sponsorship agreements have revealed that sponsors can review, terminate, and publish a
study without needing the original authors’ consent (Lundh et al., 2012). However,
whether this translates to reducing publication rates is not clear. While some studies
suggest industry funding is associated with decreased odds of publication, others did not
find such an association. On the one hand, Jones et al. (2013), Kasenda et al. (2014), and
Rosenthal et al. (2015) each reported a significant decrease in odds of publication
associated with industry funding, relative to other funding sources (OR 0.48 [0.31, 0.74],
0.60 [0.43, 0.83], and 0.33 [0.12, 0.95], respectively). Data from von Elm et al. (2008)
revealed comparable results (crude OR 0.55 [0.35, 0.86]) and Pica & Bourgeois (2016)
reported an OR of 0.45 [0.27, 0.74] at 24 months after trial completion. On the other
hand, Al-Durra et al. (2018), Blümle et al. (2008), Blümle et al. (2014), and Chahal et al.
(2012) did not find a significant association (OR 0.75 [0.44, 1.28], 0.89 [0.42, 1.87], 0.92
[0.61, 1.37], and 0.28 [0.04, 1.79], respectively), along with Kirkham et al. (2016) (RR
1.20 [0.86, 1.67]). Reviewing the association between industry funding and time to
publication revealed similar insights. Pica & Bourgeois (2016) found a significantly
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lengthened time to publication associated with industry funding (33 vs. 24 months, p <
0.001), but Khan et al. (2014) did not find an association (HR 1.0 [0.6, 1.5]). Thus, there
was no clear consensus on the relationship between funding source and likelihood of
publication or time to publication. Heterogeneity and lack of power among existing
studies may have prevented definitive conclusions.
Only one of the studies in our review assessed the type of intervention. Specifically,
Rosenthal et al. (2015) did not find a significant association between surgical studies and
odds of publication, compared to non-surgical studies (OR 0.76 [0.50, 1.13]).
Statistically significant results, irrespective of direction, was one of the most consistent
predictors for publication, likely because researchers may be more motivated to publish
such results that are deemed interesting. Both Dickersin & Min (1993) and Khan et al.
(2014) reported that statistically significant results were associated with dramatically
increased odds of publication (OR 12.3 [2.54, 60] and 4.3 [1.8, 10.2], respectively).
Likewise, Tfelt-Hansen (2009) suggested that industry studies that failed to show
adequate treatment benefits or superiority to alternatives were less likely to be published.
Statistically significant results were also associated with significantly shorter time to
publication (HR 1.9 [1.2, 2.8]) (Khan et al., 2014). Thus, statistical significance of results
seems to be positively associated with both likelihood and speed of publication.
Study enrollment size was also positively associated with publication. Larger studies may
have more statistical power, resources, and renown, increasing the probability of
publication. Unfortunately, there was little replicable consistency in how its association
was measured and some thresholds were seemingly arbitrary. Of the seven studies that
analyzed the association between sample size and publication, three of them
dichotomized size by the median (Blümle et al., 2008; Blümle et al., 2014; von Elm et al.,
2008). Both Blümle et al. (2008) and Blümle et al. (2014) had a median of 120, with the
latter reporting a significant association (Chi2 test of independence, p = 0.01). With a
median of 236, von Elm et al. (2008) also found that size was associated with an increase
in odds of publication (OR 2.04 [1.23, 3.39]). One study dichotomized using a threshold
of 100 participants (Dickersin & Min, 1993). The remaining three studies divided size
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into three or more quartiles, increments, or categories, with all of them reporting a
positive association between size and publication (Al-Durra et al., 2018; Kasenda et al.,
2014; Pica & Bourgeois, 2016). Both Al-Durra et al. (2018) and Pica & Bourgeois (2016)
used Chi2 tests (p = 0.001 and p < 0.001, respectively). Kasenda et al., (2014) reported a
small but significant increase with an OR of 1.05 [1.03, 1.09] per 100 increase in size.
Only two of the seven studies did not find an association (Blümle et al., 2008; Dickersin
& Min, 1993), likely due to a lack of statistical power in both cases. Nevertheless, none
of the studies suggested a decrease in publication associated with enrollment size.
Early trial discontinuation was another factor evaluated in studies of publication bias.
Intuitively, studies that failed to reach completion are less likely to reach publication as
they may not have sufficient results to publish. Kasenda et al. (2014) and Rosenthal et al.
(2015) estimated that discontinuation is associated with decreased odds of publication by
as much as 70–75% (OR 0.31 [0.23, 0.44] and 0.24 [0.08, 0.69], respectively). With 16–
25% of trials not reaching completion (Blümle et al., 2014; Kasenda et al., 2014; Pica &
Bourgeois, 2016), trial discontinuation could be a major influence on failure to reach
publication. Characteristics such as enrollment size (Pica & Bourgeois, 2016) and harm
outcomes (Rosenthal et al., 2015) did not seem to be significantly associated with
likelihood of discontinuation. While Rosenthal et al. (2015) did not find an association
between industry funding and trial discontinuation (0.60 [0.20, 1.85]), Pica & Bourgeois
(2016) found that industry funding was associated with a significant decrease in odds of
discontinuation (0.46 [0.27, 0.77]), which somewhat contradicts its negative influence on
publication. One interpretation could be that industry sponsorship and associated
infrastructure may increase impetus and accountability for researchers to complete trials
but not necessarily to publish them. Although discontinuation is not a focus of our study,
reviewing its prevalence and predictors may still be relevant to our understanding of nonpublication as a whole.

2.7 Knowledge Gap
Our literature review revealed some shortcomings in existing studies that we hoped to
address. A prominent issue was the general lack of sufficient sample size to adequately
explore associations between study characteristics and publication. Most studies did not
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use multivariable regression analysis, which would have improved effect estimates and
mitigated confounding. Another issue was the lack of consistency in analyzing
enrollment size, particularly as a dichotomous or categorical variable. The difficulty in
deciding on a consistent method of categorization suggests that size should be kept as a
continuous variable instead, which could produce more valid results in analysis.
The majority of existing studies calculated a crude proportion published to quantify nonpublication. Determining the rate of publications that include their prespecified primary
outcome (Al-Durra et al., 2018) may be a more effective measure, as it considers
selectively reported primary outcomes. Most studies also did not consider potential
changes in publication measures and study characteristics over time, even though it
would be unreasonable to assume them to be static. Time to publication may be another
important factor in publication bias because studies may vary in how long it takes them to
publish. However, analysis of potentially associated characteristics for publication time is
scarce. Studies published sooner may also have greater impact than those published later,
which makes shortening publication times beneficial. Plus, none of the existing studies
measured time to publication from the registry start date or properly calculated effect
estimates in terms of absolute difference in time. Furthermore, the quality of the
protocols and registry entries themselves were largely ignored. Not only would poor
outcome descriptions make it difficult to find discrepancies, but better documentation
may also indicate better planning, which could increase likelihood of publication.
The heterogeneity in publication rates suggests that likelihood of publication and
associated factors may vary widely, especially by region and data source. To ensure the
applicability of our results, we determined we needed to quantify publication bias
specific to research conducted in London, Ontario. To the best of our knowledge, no such
study on publication bias has been conducted. While a broad tool like the FDAAA
TrialsTracker may be useful as general reference, we have noted that it is lacking in
sensitivity for this region. The fact that it suggests a mere 20% reporting rate (EBM
DataLab, 2018) is all the more reason a proper in-depth study is necessary to affirm or
correct those findings. To that end, data from a public registry would likely allow us to
find a greater number and a broader range of relevant studies from London, Ontario.
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Table 1
Summary of literature review results for publication rate

Study

Data Source

Al-Durra et al., 2018

ClinicalTrials.gov

Sample

Proportion

Predictors

0.73

size*, industry,

Size
556

prospective
Blümle et al., 2008

Ethics protocols

299

0.48

industry

Blümle et al., 2014

Ethics protocols

917

0.52

size*, industry

Chahal et al., 2012

ClinicalTrials.gov

34

0.59

industry

Dickersin & Min,

NIH-funded trials

198

0.93

positive*, size,

1993
Jones et al., 2013
Kasenda et al., 2014

industry
ClinicalTrials.gov

585

0.71

industry†

Ethics protocols

1017

0.56

size*,
industry†,
discontinue†

Khan et al., 2014

ClinicalTrials.gov

143

0.64

positive*,
prospective

Kirkham et al., 2016

Ethics protocols

308

0.54

Menzel et al., 2007

Ethics protocols

99

0.7

Pang & Loke, 2011

GSK registry

54

0.47

Pica & Bourgeois,

ClinicalTrials.gov

559

0.57

2016

industry

size*,
industry†
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Rosenthal et al., 2015

Ethics protocols

863

0.66

industry†,
discontinue†,
surgical

Tfelt-Hansen, 2009

GSK registry

6

0

negative

von Elm et al., 2008

Ethics protocols

451

0.52

size*,
industry†

Note. This table lists the studies included in our literature review as well as their baseline
data sources, sample sizes, and general findings. Parameter estimates and evaluated
predictors for proportion published are shown.
*Significantly increases publication rate (p < 0.05).
†Significantly decreases publication rate (p < 0.05).
Table 2
Summary of literature review results for time to publication
Study
Al-Durra et al., 2018

Time (Months)

Predictors

post-start median 48–72

Jones et al., 2013

post-completion median 27

Khan et al., 2014

post-completion median 38

positive*, industry,
prospective

Menzel et al., 2007

post-approval median 46

Pica & Bourgeois, 2016

post-completion mean 29

industry†

Note. This table lists the parameter estimates and evaluated predictors for time to
publication from the studies included in our literature review.
*Significantly shortens time to publication (p < 0.05).
†Significantly lengthens time to publication (p < 0.05).
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Chapter 3

3

Visuals for Temporality of Publication

To the best of our knowledge, graphing publication temporally has not been
commonplace when studying publication bias. Such graphs could show variations in
publication rates over time and supplement conventional proportion statistics. In
particular, a temporal graph would allow the observation of influences from past
landmark events on publication rates. While some studies have touched on the concept,
few have done so in the capacity we have planned. This chapter aims to summarize the
existing work that inspired and helped develop our graphics.

3.1 Publication Rates Over Time
The concept of graphing the proportion of published studies across time as a variable has
been done in other contexts. Tsujimoto et al. (2019) constructed a cumulative incidence
curve for publication rate of systematic reviews over a period of roughly 6 years. This
visual approach revealed an almost logarithmic curve with a steep initial incline around 1
year, which coincided with a median time to publication of 1.2 years (Figure 1)
(Tsujimoto et al., 2019). Strand et al. (2017) employed a similar idea, but instead
constructed a Kaplan-Meier survival curve and focussed on clinical trials (Figure 2).
With time of funding as their starting point and publication of main results as their
survival criteria, their graph was in stark contrast to that of Tsujimoto et al. (2019) and
revealed an exponential curve with a steep incline much later, which corresponded with a
longer median time to publication of 7.1 years (Strand et al., 2017). Comparing these
findings demonstrates an observable difference between the publication trends of
systematic reviews and clinical trials, with the bulk of systematic reviews being
published much sooner.
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Figure 1
Cumulative publication rate of systematic reviews with statistically significant (SS)
results (dashed line) and those without SS results (solid line)

Note. Cumulative incidence curves for publication of systematic reviews over 6 years.
From “Statistical significance did not affect time to publication in non-Cochrane
systematic reviews: A metaepidemiological study,” by Y. Tsujimoto, Y. Tsutsumi, Y.
Kataoka, H. Tsujimoto, Y. Yamamoto, D. Papola, G. H. Guyatt, S. Fukuhara, and T. A.
Furukawa, 2019, Journal of Clinical Epidemiology, 115, p. 25–34
(https://doi.org/10.1016/j.jclinepi.2019.06.015). Copyright © 2019 by Elsevier Inc.
Reprinted with permission.
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Figure 2
Kaplan-Meier survival curve (and 95% CIs as dashed lines) for time from funding to
main paper for all papers combined

Note. Kaplan-Meier survival curves for publication of clinical trials over 8 years. From
“Time to publication for publicly funded clinical trials in Australia: An observational
study,” by L. B. Strand, P. Clarke, N. Graves, and A. G. Barnett, 2017, BMJ Open, 7(3),
p. e012212 (https://doi.org/10.1136/bmjopen-2016-012212). Copyright © 2017 by BMJ
Publishing Group Ltd. Reprinted with permission.
A plausible explanation for the difference in median time to publications would be the
difference in amount of time and work necessary to carry out the two types of studies.
However, if that were the sole reason, one would expect a simple horizontal translation
going from one graph to the other. The clear differences in overall trends cannot be so
easily explained and would not have been as apparent with the conventional statistics
alone. Thus, the ability to document and compare publication trends shows the
importance of visual representation and temporality in the analysis of publication rates.
Both of the temporal line graphs described above (Figure 1, Figure 2) used standardized
timescales of relative years, showed the cumulative proportion of studies published
instead of frequency, and had relatively narrow time ranges of 6 to 8 years. While these
design decisions adequately served their intended purposes, both of these pre-existing
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graphs were limited in their ability to display historical trends over longer periods of
time. To that end, Blümle et al. (2014) provided an alternative method in constructing a
bar graph of publication frequency by calendar year. Unfortunately, this graph was also
limited and only showed the publications of ethics submissions made in 2000 alone.
Thus, our goal was to expand on this concept and create a graph that would both use
absolute time in years and span a much longer timeframe.

3.2 Leaky Buckets and Icon Arrays
A leaky bucket diagram is a graph that shows losses across stages of a sequential process,
with each stage being represented by a rectangular “bucket” (Glasziou, 2005). Such a
graph may be useful in portraying the losses in studies on their way to publication, where
the “water” dripping from each bucket represents the proportion of studies that failed to
reach the next stage. While a standard bar graph may accomplish the same task, the leaky
bucket diagram may better resonate with readers as a relevant analogy due to the implied
flow across the diagram and the ability to directly compare proportions between each
stage. To the best of our knowledge, using registry data to construct such a diagram has
not yet been done.
Blümle et al. (2014) was a key inspiration because they used metadata from a database of
study proposals submitted for ethics review, which was comparable to information in
public registries. Their results included the number of studies that were approved, started,
completed, and published. While these statistics were not explicitly portrayed as stages in
the research process, we believed they could be re-interpreted as such and have adapted
them into a leaky bucket diagram as proof of concept (Figure 3).
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Figure 3
Leaky bucket diagram

Note. Leaky bucket diagram showing the proportion of studies that progressed to each
stage of the research process. Percentages along the bottom indicate relative proportion of
studies lost from the previous stage. Data adapted from “Fate of clinical research studies
after ethical approval – follow-up of study protocols until publication,” by A. Blümle, J.
J. Meerpohl, M. Schumacher, and E. von Elm, 2014, PLoS ONE, 9(2), p. e87184
(https://doi.org/10.1371/journal.pone.0087184). CC BY 4.0.
Unfortunately, an inherent weakness of a leaky bucket diagram was its lack of ability to
convey multiple values per stage without becoming too complicated, since a single value
is used to summarize the differences between stages. Tsujimoto et al. (2019) showed the
effectiveness of conveying multiple publication values in the same graph, specifically the
proportion of significant and non-significant studies published. This suggested another
type of graph may be necessary: the icon array (Figure 4) (de Vries et al., 2018). The
icons in the array represent chunks of equal size and are grouped together to convey the
number of entities per stage, similar to a leaky bucket diagram. The benefit of icon arrays
is the ability to colour code these icons, which allows for a clear and convenient method
of describing the distribution of any number of characteristics within a given stage. For
the purposes of our study, we planned to create an icon array that showed the distribution
of positive and negative studies across each stage of the progression from study
registration to publication.
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Figure 4
The cumulative impact of reporting and citation biases on the evidence base for
antidepressants

Note. Icon array using circles to represent the distribution of studies across each category
of bias. From “The cumulative effect of reporting and citation biases on the apparent
efficacy of treatments: The case of depression,” by Y. A. de Vries, A. M. Roest, P. de
Jonge, P. Cuijpers, M. R. Munafò, and J. A. Bastiaansen, 2018, Psychological Medicine,
48(15), p. 2453–2455 (https://doi.org/10.1017/S0033291718001873). Copyright © 2018
by Cambridge University Press. Reprinted with permission.
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Chapter 4

4

Methods

This chapter describes our retrospective cohort of all studies registered on
ClinicalTrials.gov affiliated with London, Ontario. The primary objective of our study
was to determine the proportion of registered studies that were ultimately published and
what were the associated study characteristics. Secondary objectives were to estimate
time to completion and time to publication for studies following study start. Lastly, we
created visualizations for changes in publication over time.

4.1 Registered Studies
ClinicalTrials.gov is a global clinical trial registry hosted by the United States National
Library of Medicine, within the National Institutes of Health (NLM, n.d.). We selected
this registry as the source to identify our cohort of registered studies from London,
Ontario since it is the largest clinical trials database and remains the most common
avenue for registering studies in North America.
The registry outcome descriptions were assumed to be each study’s preconceived and
planned outcomes prior to being conducted. These served as reference for determining
the quality of protocols and potential discrepancies in outcome reporting. When
applicable, only the registry’s most recent information at the time of our search was used.
Any interventional studies (i.e., clinical trials) that mentioned “London, Ontario” in their
affiliation or location, registered from ClinicalTrials.gov inception to the end of 2017,
were eligible for inclusion. Observational and expanded access (treatment of patients who
cannot participate in a clinical trial) studies, as indicated in the registry, were excluded.
Prior exploratory screening showed that limiting to studies as late as 2017 ensured a
reasonable cohort size of over 2000 studies while also allowing more than 2 years for
registered studies to reach publication.
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4.2 Published Studies
The Ovid search engine (Wolters Kluwer, n.d.) was used to find corresponding
publications for all registered studies (regardless of study status), via NCT number, in the
following databases: Medline, Embase, PsycInfo, and Western Libraries. These databases
were likely to reasonably capture any potential publication in journals or other
publication outlets. Our search method assumed that publications would specifically
mention their associated NCT numbers and that they would be indexed in each of our
searched databases. However, exploratory searches found that NCT numbers were a
practical and reliable method of matching any registered study on ClinicalTrials.gov to a
corresponding publication if one existed. The cut-off date for primary publications was
July 31, 2020, meaning a minimum time for publication window of about 2.6 years from
time of registration until publication. Published manuscripts, journal articles, and
abstracts were included. Review articles, presentations, and letters or editorials were
excluded. Protocols were also excluded unless they included preliminary or final results.
The abstracts of search results were manually screened to determine whether the
information in the title, objectives, and outcomes reasonably matched those in the registry
entries. Due to the possibility of results being published under different authorship
(Doshi, 2013), the names of the researchers were not used in matching. The screening
was generally restricted to publication abstracts. However, the full-text was retrieved for
screening if a standard abstract including the aforementioned elements was not found. If
at least one result matched a corresponding registry entry, the study was considered
published. In the case of multiple matching results, only the publication with the earliest
date was used. This was to mitigate any advantages from multiple publications, such as
having more time on later publications. Only studies that included results were
considered as publications. Both descriptive and comparative statistics were accepted as
results if indicated as outcomes by the publication’s study objectives.
The earliest available publication date was recorded as the study publication date,
including electronic publications and publications ahead of print. When the publication
date was not available, the acceptance date was used instead. If neither was available,
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then the submission date was used. For conference abstracts without a publication date,
the earliest conference date was used.

4.3 Study Characteristics and Outcomes
Metadata for ClinicalTrials.gov registry entries were exported in .csv format and
converted to a Microsoft Excel spreadsheet (.xlsx). The NCT number, year, title,
intervention(s), and outcome(s) were used for study identification. Other noteworthy
metadata included study status (completed, ongoing, terminated, etc.), study design
(RCT), intervention type (surgery/procedure, drug, or other), funding source, and
enrollment size. Study registration date (first posted on ClinicalTrials.gov), start date
(first participant enrolled), primary completion date (last participant examined for
primary outcome measure), and overall completion date (last participant examined for all
outcome measures) were recorded as indicated in the registry (NLM, n.d.). Estimated
values and dates were accepted when actual values were not available. When applicable,
we calculated the time in months from the study start date to the study primary outcome
completion date, overall completion date, and date of first publication.
For each study, we recorded whether randomized allocation was used to distribute
participants between treatment groups, as opposed to non-randomized allocation (i.e.,
single group, manual assignment, etc.). A study was considered prospectively registered
if the estimated or actual start date occurred later than the date of initial registration, and
retrospectively otherwise. Funding sources were recorded as industry,
academic/government/other, or both. Studies with no stated funding were included in
“other”. For the purposes of analysis, any industry funding at all, compared to no industry
funding, was used as a study characteristic. Regarding intervention types, surgical studies
were compared to non-surgical studies (drug or other) while drug studies were compared
to non-drug studies (surgery or other).
In the registry, the inclusion of each study’s planned outcome(s) was recorded. If primary
and secondary outcomes were not clearly indicated in the registry entry, the first-listed
outcome was considered primary. Partially inspired by Saldanha et al. (2014), the
completeness of primary outcome descriptions was judged using three criteria: a specific
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metric to assess the outcome (e.g., change in heart rate, not “heart health”); a unit or scale
of measurement for the relevant data (e.g., beats per minute); and at least one timepoint
of outcome ascertainment (e.g., after 1 hour).
Among publication abstracts, the inclusion of planned primary outcome at all was
recorded. When multiple primary outcomes were mentioned in the registry, only the firstlisted was considered. This was to prevent any potential advantages from studies that
mentioned more than one planned primary outcome (i.e., more opportunities to obtain
favourable results). A published outcome only had to fit the registry outcome metric to be
considered a match with the planned outcome. We decided not to require additional
outcome criteria, such as matching measures and timepoints, because not all registry
entries provided these details. Although complete definitions would be ideal (Saldanha et
al., 2014), we believed it would be improper to penalize those that simply put more effort
into their outcome descriptions, since any discrepancies with the publication would only
be apparent among registry entries that included such details in the first place.
Planned primary outcomes that were not reported as primary outcomes or were not
reported at all in the publication were considered switched. If primary and secondary
outcomes were not clearly indicated in the abstract, primacy was used as follows. Among
the listed outcomes, the first half of the list was considered primary while the second half
was considered secondary. If there was an odd number of outcomes, the middle outcome
was considered primary. For example, if there were a total of five outcomes described
with no clear differentiation, only the first three would be considered primary outcomes.
Study registry entries that did not specify planned outcomes were not included. We also
excluded descriptive and summary statistics unless otherwise stated as being the primary
objective of the study. By definition, the difference between studies that published any
results and those that switched their primary outcome would equal the number of studies
that published their planned primary outcome as primary.
To assess favourability of study results, a study was considered positive if at least one
published primary outcome was both statistically significant and directionally in favour
of the study hypothesis, and negative otherwise. Since statistical significance and
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direction are not usually applicable to descriptive outcomes, they were considered
inherently positive when applicable.

4.4 Statistical Analysis
Data analysis was performed in Stata 16 (StataCorp LLC, College Station, TX).
Summary statistics were reported for relevant metadata, characteristics, and outcome
variables, in the form of medians, means, proportions (as percentages), or sums. A paired
t-test and McNemar's Chi2 test were conducted to determine whether overall proportion
published and proportion published with primary outcome were significantly different
from one another. The continuous variables of time to study completion for primary
outcome, time to overall study completion, time to first publication, and enrollment size
were plotted on histograms to detect skew. Heavy skew would indicate the median was
more representative than the mean as a summary statistic and vice versa. Additionally,
the prevalence of various dichotomous study characteristics each year was calculated.
The number of registered studies that began enrollment each year and the annual average
sample sizes were also recorded.
Log-binomial regression (log link function) was used to analyze the relationship between
our dichotomous study characteristics and publication status (i.e., published or not
published), as well as publication with planned primary outcome, in the form of relative
risk. Relative risk was preferred over odds ratios as it tends to be more conservative. The
main study characteristics used were randomized design (RCT), prospective registration,
industry funding, surgical study, and drug study. An additional set of models were run to
analyze the effects of registry outcome description quality, among entries that had
descriptions, using each of our three criteria as individual covariates and adjusting for the
main study characteristics listed above. For each model, multicollinearity between
variables was checked by calculating the variance inflation factors (VIF) for each of the
covariates. VIF values greater than 10 would indicate presence of multicollinearity
(UCLA, n.d.). Due to a high degree of multicollinearity between the outcome description
covariates (Table C5), they were regressed separately. Favourability of results was not
included as a covariate for publication because we lacked data on the results of
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unpublished studies. As our study design only assessed results from published studies, the
inclusion of positive results in the regression model would heavily skew our regression.
Enrollment size was kept as a continuous variable, instead of dichotomization into a
dummy variable, as we lacked justification for arbitrary divisions. Due to convergence
issues with binomial regression, we used modified Poisson regression (robust variance)
(Zou, 2004) to examine the relationship between enrollment size and publication, as well
as publication with planned primary outcome, adjusting for the main study characteristics
included in our log-binomial model. To check for overdispersion, likelihood ratio tests
were conducted between Poisson regression and analogous negative binomial regression
models. These tests did not show evidence of overdispersion (Table C9, Table C10),
justifying the applicability of Poisson regression. Relative risk, in the form of incidence
rate ratios (IRR), was reported for increases of 1000 participants in order to improve
readability. Pearson and point-biserial correlation coefficients were also calculated,
between enrollment size and publication, as supplementary statistics.
Among published studies, a multiple linear regression model was used to analyze the
relationship between our dichotomous study characteristics and time to first publication.
Linear regression was preferred for its ease of understanding and absolute output
statistics (i.e., differences in time). The characteristics included were positive results,
randomized design, prospective registration, industry funding, surgical study, and drug
study. The assumptions of normality, homoskedasticity, and linearity were checked
(Figure C1, Figure C2, Figure C3, Table C11, Figure C4). Due to substantial right skew,
the outcome variable time to publication was natural log-transformed. A robust variance
estimate was also used due to potential heteroskedasticity. Linearity was met because
binary variables are inherently linearly related to the outcome.
In addition to linear regression, we were interested in exploring the feasibility of time-toevent analysis to further evaluate time to publication for positive versus negative studies.
To that end, we interpreted time to publication as the length of time observed from
baseline (first patient enrolled) to our event of interest, publication. A cumulative
incidence graph was generated, and a log-rank test was performed, to assess the
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association between positive results and time to publication. We also attempted to run a
post hoc multivariable Cox regression model for time to publication using the same
covariates as our multiple linear regression model. However, since both the Schoenfeld
residuals test and our log-log plot for positive results demonstrated that the proportional
hazards assumption was not met (Table C14, Figure C5), the parametric Weibull
regression was used instead. We have included the regression output in our appendices as
reference (Table C15).

4.5 Graphs and Visuals
One of our additional objectives was to convey our data visually using various graphs.
When applicable, proportions were shown as percentages.
The proportion of studies published, by year started (first participant enrolled), was made
into a bar graph to show potential trends over time. To complement this graph, a Chi2 test
and one-way ANOVA were used to examine whether there was any relationship between
study start year and publication rates. Analysis was limited to 1997 and onwards due to
sparsity of data before that year (Table D2), which roughly coincides with FDAMA in
1997 and the formalization of ClinicalTrials.gov (NLM, n.d.).
In addition to the proportion of studies published, we included a post hoc estimate of
studies “Not Yet Published” for each year. This was added to mitigate the perceived
effects of right censoring, as some studies may be less likely to publish due to having less
time. To estimate this, we first assume the distribution of the time to publication variable
(Figure B3) is representative of the general timeliness of publication of studies started in
any given year within our dataset. It is worth noting that time to publication is measured
in months, ends on our publication cut-off date (July 31, 2020), and has a range of 304
months (Table 3). We calculate the length of time from the beginning of a given year to
our cut-off date, then find the equivalent percentile for this length of time in the
distribution of the time to publication variable. This percentile represents the estimated
proportion of studies started that year that have been published out of all studies that will
be published, at least within the ~25 years of our time to publication variable. Dividing
the actual proportion by the percentile allows us to calculate the estimated proportion of
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all registered studies that will be published. The difference between the estimated and
actual proportion is thus our estimate for proportion of studies that have yet to be
published from that given year. This process was repeated for each year (Table D3) and
was shown as part of the stacked bars on our graph.
The registry metadata we collected on study statuses of unpublished studies was
simplified into three mutually exclusive study categories: completed, ongoing, or
stopped. Studies that were “completed” maintained their original registry definition.
“Ongoing” studies were those that were recruiting, enrolling, or active. “Stopped” studies
included studies that were withdrawn, suspended, terminated, or had unknown status. The
frequencies and proportions of studies in each category, along with published studies,
were then graphed by year started in separate stacked bar graphs.
To supplement publication over time, a multiple line graph was created to show changes
in the prevalence of our main dichotomous study characteristics over the years. This
included randomized design, prospective registration, industry funding, surgical studies,
and drug studies.
A leaky bucket diagram (Glasziou, 2005) was created to show the proportion of studies
that progressed through the stages of the research process to publication. The stages were
registration, study start, completion, publication, and publication with planned primary
outcome at all.
An icon array was also generated to show the distribution of positive and negative studies
that were registered, completed, published, and published with planned primary outcome
at all. Since we did not have any data on the results of unpublished studies, they could not
be accurately represented. Under the circumstances, unpublished studies may be
considered negative in interpretation, as they inherently failed to produce and publish any
results in the context of our study. However, this would likely overestimate the
proportion of negative studies among unpublished registered or completed studies. While
not a direct representation, we hoped it could serve as a proof of concept.
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Chapter 5
Results

5

The following chapter will report the results of our statistical analysis and data synthesis,
starting with a summary of the baseline characteristics for our cohort of registered studies
from London, Ontario. Analyses for the outcome variables of publication and time to
publication are reported separately. The last section will be a description of the visual
graphics generated to represent our data. All data is as of July 31, 2020.

5.1 Descriptive Statistics of Registered Studies From
London, Ontario
Table 3
Summary statistics for count and continuous variables
Statistic

N

Median

IQR (Q1, Q3)

Mean

SD

Min

Max

2446

-

-

-

-

-

-

2410

250

610 (80, 690)

980

5093

0

164946

2435

35

36 (21, 57)

44

34

0

340

2298

41

48 (23, 71)

53

43

0

340

925

53

39 (36, 75)

63

41

1

304

Counts
Registered
Studies
Enrollment Size*

Time Intervals (Months)
Primary Outcome
Completion*
Overall
Completion*
Publication*
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Note. This table shows the total number of registered studies and the summary statistics
for our count/continuous variables: study enrollment size, time to complete examinations
for primary outcome, time to complete examinations for all outcomes, and time to first
publication. N = number of distinct observations, IQR = interquartile range, SD =
standard deviation, Min = minimum observed value, Max = maximum observed value.
*Right-skewed (Figure B1, Figure B2, Figure B3, Figure B5).
A total of 2446 study registry entries were included in our dataset, of which 2410
included data on actual or expected enrollment numbers. Median study enrollment size
was 250 participants. In chronological order, the median time for a study to finish
ascertaining its primary outcome was 35 months, to complete the entire study was 41
months, and to publish their results was 53 months. All time interval variables showed
strong evidence of right-skew. (Table 3)
From 1997 to 2017, the annual average enrollment size of randomized studies decreased
over the years from 4455 to 1676 participants, while the average enrollment size of nonrandomized studies increased from 151 to 284. Overall study enrollment sizes decreased
from an annual average of 2542 in 1997 to 1484 in 2017. (Table B3)
Table 4
Prevalence and frequencies of dichotomous variables
Statistic

Prevalence (%)

Frequency (N = 2446)

Published

38*

925

Primary Outcome

30*

743

8

197

84

2050

Published
Primary Outcome
Switched
RCT
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Prospective Registration

49

1206

Industry Funding

65

1565

Surgical Study

11

259

Drug Study

72

1752

Outcome Mentioned

96

2358

Metric Defined

68

1664

Measurement Defined

88

2152

Timepoint Defined

92

2247

Note. This table shows the percentages and frequencies of our dichotomous parameters
and study characteristics: publication, publication with primary outcome at all,
omission/demotion of primary outcome, randomized design (RCT), prospective
registration, any industry funding, surgical intervention, and drug intervention. Registry
outcome characteristics are also included: mention of any outcome at all, a specific
metric, a unit/scale of measurement, and a timepoint of ascertainment.
*Significantly different via paired t-test and McNemar’s Chi2 test, both p < 0.001 (Table
B1, Table B2).
Overall, most studies were RCTs (84%) and received some form of industry funding
(65%). Fewer than half (49%) were registered prior to beginning the study. For
intervention types, 11% were surgical while 72% were drug studies. Nearly all registry
entries mentioned an outcome of interest (96%). However, 32% of them did not provide
their metric for assessing their outcome, 12% did not mention the measurement to be
used, and 8% did not give at least one timepoint for outcome ascertainment. (Table 4)
In total, 38% of all studies were published. Only 30% were published with their planned
primary outcome at all. About 8% of all studies switched their primary outcome in
publication either by complete omission or demotion to a secondary outcome. Demotion
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alone was rare and occurred in fewer than 1% of studies. Additionally, among published
studies, almost 85% had positive results (Table D8). (Table 4)

5.2 Probability of Publication
Table 5
Adjusted RR for association between study characteristics and study publication as well
as publication with primary outcome
Predictor

RR

95% CI

p value

RCT

1.46

1.22, 1.73

<0.001

Prospective Registration

1.15

1.04, 1.26

0.006

Industry Funding

1.67

1.45, 1.92

<0.001

Surgical Study

0.86

0.69, 1.09

0.22

Drug Study

1.26

1.09, 1.45

0.002

Publication with Any Results

Publication with Primary Outcome
RCT

1.50

1.22, 1.83

<0.001

Prospective Registration

1.20

1.06, 1.34

0.003

Industry Funding

1.85

1.56, 2.19

<0.001

Surgical Study

0.82

0.62, 1.08

0.16

Drug Study

1.16

0.98, 1.36

0.08

Note. This table shows the estimated relative risks (RR) for publication and publication
with primary outcome at all, using multivariable log-binomial regression, associated with
our dichotomous study characteristics: randomized design (RCT), prospective
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registration, any industry funding, surgical intervention, and drug intervention. CI =
confidence interval.
Relative risk for publication with any results was significantly increased for randomized
versus non-randomized study design (RR 1.46 [95% CI: 1.22, 1.73]), prospective versus
retrospective registration (1.15 [1.04, 1.26]), and industry versus other funding (1.67
[1.45, 1.92]). Similarly, relative risk for publication of planned primary outcome was also
significantly increased for randomized design (1.50 [1.22, 1.83]), prospective registration
(1.20 [1.06, 1.34]), and industry funding (1.85 [1.56, 2.19]). Surgical versus non-surgical
studies were not significantly associated with publication or publication with primary
outcome (0.86 [0.69, 1.09] and 0.82 [0.62, 1.08], respectively). Drug versus non-drug
studies were significantly associated with increased publication with any results (1.26
[1.09, 1.45]) but not publication with primary outcome (1.16 [0.98, 1.36]). (Table 5)
Table 6
Adjusted RR for association between individual outcome description quality criteria and
study publication as well as publication with primary outcome
Predictor

RR

95% CI

p value

Metric

1.61

1.39, 1.85

<0.001

Measurement

2.01

1.50, 2.68

<0.001

Timepoint

2.51

1.62, 3.88

<0.001

Publication with Any Results

Publication with Primary Outcome
Metric

1.65

1.40, 1.95

<0.001

Measurement

1.80

1.32, 2.45

<0.001

Timepoint

2.11

1.34, 3.33

0.001
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Note. This table shows the estimated relative risks (RR) for publication and publication
with primary outcome at all, using multivariable log-binomial regression, associated with
our criteria for registry outcome description quality: mention of a specific metric, a
unit/scale of measurement, and a timepoint of ascertainment. Regression models were run
separately for each criterion due to high multicollinearity (Table C5, Table C6) and
adjusted for randomized design, prospective registration, any industry funding, surgical
intervention, and drug intervention. CI = confidence interval.
Relative risk for publication with any results was significantly and positively associated
with defining the metric in the registry entry (1.61 [1.39, 1.85]), mentioning the
measurement in the registry entry (2.01 [1.50, 2.68]), and describing at least one
timepoint of outcome ascertainment in the registry entry (2.51 [1.62, 3.88]). Similarly,
relative risk for publication with planned primary outcome was also significantly
associated with including the metric (1.65 [1.40, 1.95]), measurement (1.80 [1.32, 2.45]),
and timepoint (2.11 [1.34, 3.33]) in the registry entry. (Table 6)
Table 7
Adjusted IRR for association between enrollment size and study publication as well as
publication with primary outcome, per 1000 increase in enrollment size
Predictor

IRR

95% CI

p value

1.007, 1.021

<0.001

1.008, 1.021

<0.001

(per 1000)
Publication with Any Results
Enrollment Size

1.014

Publication with Primary Outcome
Enrollment Size

1.015

Note. This table shows the estimated incidence rate ratios (IRR) for publication and
publication with primary outcome at all, using multivariable modified Poisson regression,
associated with study enrollment size. The model was adjusted for randomized design,
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prospective registration, any industry funding, surgical intervention, and drug
intervention. IRRs are reported for increases of 1000 participants. CI = confidence
interval.
Enrollment size was significantly and positively correlated with likelihood of publication
(Table C1, Table C2). Relative risk for an increase in enrollment size was significantly
associated with both publication and publication with primary outcome at all (IRR 1.014
[1.007, 1.021] and 1.015 [1.008, 1.021] per increase of 1000, respectively). (Table 7)

5.3 Time to Publication
Table 8
Association between study characteristics and time to publication
Predictor

Difference

95% CI

p value

(Months)
Positive Results

-9.70

-15.75, -3.65

0.002

RCT

4.05

-3.84, 11.93

0.31

Prospective Registration

-16.12

-21.17, -11.07

<0.001

Industry Funding

-22.72

-30.43, -15.00

<0.001

Surgical Study

9.28

-2.01, 20.57

0.11

Drug Study

9.58

1.76, 17.40

0.02

Note. This table shows the estimated difference in months for time to publication, using
multiple linear regression, associated with our dichotomous study characteristics: positive
results, randomized design (RCT), prospective registration, any industry funding, surgical
intervention, and drug intervention. CI = confidence interval.
Among published studies, positive results were significantly associated with decreased
time to publication by almost 10 months relative to non-significant or unfavourable
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results. Randomized design was not significantly associated with a change in time to
publication (~4 months, p = 0.31). Prospective registration was significantly associated
with decreased time to publication by over 16 months relative to retrospective
registration. Receiving any form of industry funding was significantly associated with
decreased time to publication by almost 23 months relative to only receiving funding
from non-industry sources. Surgical studies were not significantly associated with a
change in time to publication compared to non-surgical studies (~9 months, p = 0.11),
while drug studies versus non-drug studies were significantly associated with an increase
in time to publication of almost 10 months. (Table 8)

Figure 5. Cumulative incidence of publication for positive versus negative studies. This
cumulative incidence graph shows the survival curves for study publication, after their
first participant was enrolled, of published studies with positive (dashed line) and
negative (solid line) results. Log-rank test showed a statistically significant difference
between the survival curves (p < 0.05) (Table C13).
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Both the positive and negative study survival curves had a sharp initial incline until about
100 months, followed by a plateau. The overall 50% cumulative incidence roughly
coincides with our median time to publication of 53 months (Table 3). While the initial
incline was almost immediate for positive studies, negative studies did not have their first
incidence of publication until around 15 months. Overall, positive studies were
consistently published sooner than negative studies, which was confirmed to be
statistically significant via log-rank test. (Figure 5)

5.4 Graphics

Figure 6. Study publication rates by start year. This stacked bar graph shows the annual
percentage of all registered studies that are published or not yet published, by the year
their first participant was enrolled, up to 2017. FDAMA (1997) and ICMJE (2005) are
indicated by the vertical dashed lines.
Percentage values prior to 1997 were sporadic due to sparsity of data before formal
adoption of the registry and can be considered outliers. From 1997 onwards, the actual
percentage of studies published has steadily increased over time from under 20% to a
high of around 50% in 2008. This was followed by a subsequent decrease in the mid
2010s, which could be expected due to right censoring and coincides with our median
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time to publication of ~4 years (Table 3). Including not yet published studies seemed to
mitigate this decrease and continues the reasonably linear upwards trend to an estimated
percent published of nearly 60% in 2017. In addition, restricting to 1997 and onwards,
overall publication was found to be significantly associated with the year the study was
started (Table D4, Table D5). (Figure 6, Table D3)

Figure 7. Fate of all registered studies by start year (frequencies). This stacked bar graph
shows the frequency distribution of statuses of all registered studies, by the year their first
participant was enrolled, up to 2017. FDAMA (1997) and ICMJE (2005) are indicated by
the vertical dashed lines. Completed, ongoing, and stopped studies are unpublished.
Studies cannot be in more than one status group at a time.
Frequency of all registered and started studies increased dramatically following
formalization of the registry with a spike around 2005. Completed and published studies
decreased in recent years, which coincided with a large increase in ongoing studies. As
expected, the frequency of ongoing studies increased dramatically in more recent years.
Frequency of terminated and stopped studies saw a rise in the mid 2000s but seems to
have remained constant since. (Figure 7, Table D2)
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Figure 8. Fate of all registered studies by start year (proportions). This stacked bar graph
shows the percentage distribution of statuses of all registered studies, by the year their
first participant was enrolled, from 1997 to 2017.

Figure 9. Fate of completed and stopped studies by start year (proportions). This stacked
bar graph shows the percentage distribution of statuses of registered studies excluding
ongoing studies, by the year their first participant was enrolled, from 1997 to 2017.
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Figure 8 offers an alternative view to Figure 7 by displaying proportions of statuses (as
percentages) instead of frequencies. Completed studies made up the largest percentage in
the initial years, then gradually decreased over time. This decrease coincided with a
gradual increase in published studies, as well as a dramatic increase in ongoing studies in
the more recent years. Annual percentage of stopped or terminated studies seems to have
remained fairly constant (Figure 8, Table D2). Excluding ongoing studies in Figure 9 did
not substantially influence trends among published and completed studies. However, the
percentage of stopped studies each year seems to have increased in more recent years
relative to the other statuses (Figure 9).

Figure 10. Prevalence of study characteristics by start year. This multiple line graph
shows the prevalence over time of various dichotomous study characteristics among all
registered studies, by the year their first participant was enrolled, from 1997 to 2017.
The percentage of studies started each year using randomized design initially increased
from about 50% to a peak of over 90%, followed by a plateau in the mid-2000s, and has
since remained steady at a little over 80%. The percentage of studies each year that were
prospectively registered has increased almost linearly from virtually none prior to 2000 to
over 80% in more recent years, which coincides with ClinicalTrials.gov going public in
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the year 2000 (NLM, n.d.). The percentage of studies each year that were industry-funded
increased dramatically from 1997 to the mid-2000s, reaching a peak of almost 80%,
followed by a gradual decrease to about 60%. The percentage of surgical studies each
year started at 40% in 1997 but declined rapidly until the early 2000s, remaining steady at
around 10%. The percentage of drug studies each year has declined gradually over the
years from over 80% to a little over 60%. (Figure 10, Table D6)

Figure 11. "Leaks" in the research process. This leaky bucket diagram shows the
percentage of all registered studies that progress through each stage of the research
process. Percentages at each bar level represent the overall proportion of all registered
studies that reached that stage. Percentages along the bottom indicate the conditional
proportion of studies lost relative to the previous stage.
The majority of studies that are registered seem to at least be able to start in some
capacity, with only 5% failing to do so. Reaching publication seemed to be the largest
point of failure, losing about 43% of the completed studies. Failing to reach completion
after starting was another substantial leak, losing 30%. Among studies that reached
publication, about 20% did not publish their planned primary outcome at all. (Figure 11,
Table D7)
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Figure 12. Distribution of positive and negative studies across stages of the research
process. This icon array shows the proportion of studies within each stage with positive
or negative results as represented by green and red dots, respectively. Each dot represents
approximately 30 studies. Unfilled dots represent unpublished studies, which may be
considered negative. The number of positive published studies is greater than that of
completed studies due to publications from ongoing and stopped studies.
The overwhelming majority of studies that reach some form of publication had positive
results, and this distribution did not differ greatly between those published and published
with primary outcome. Studies published with any results and published with planned
primary outcome had similar proportions of positive studies. The majority of studies that
only reached registration or completion seemed to be negative or unpublished. Due to not
having the results of unpublished registered studies, the number of positive studies in the
registered and published stage are inherently the same. (Figure 12, Table D8)
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Chapter 6

6

Discussion

This chapter will provide an overview of our results. We will reiterate our main findings,
then discuss their implications and how they relate to existing literature. Potential
shortcomings from our research methodology are also addressed.

6.1 Publication Bias
Over 60% of the registered studies in our cohort failed to reach publication. If we require
that publications are published with their planned primary outcome at all, our estimate for
failure to publish is significantly increased to 70% (Table 4). As expected, our findings
were not as poor as the 80% failure rate in reporting of results for London, Ontario
research shown by the FDAAA TrialsTracker (EBM DataLab, 2018). However, our study
indicates a low rate of publication when compared to similarly conducted studies (Table
1). Furthermore, the significant decrease in proportion published when using more strict
publication outcome criteria suggests outcome switching may be prevalent among the
published studies in our cohort (Table B1, Table B2).
As one would expect, studies with randomized design were more likely to publish. This
could be because RCTs may produce more reliable results than single-arm or nonrandomized studies, which would perhaps be more readily accepted by journals. In
contrast to much of the past literature (Jones et al., 2013; Kasenda et al., 2014; Pica &
Bourgeois, 2016; Rosenthal et al., 2015; von Elm et al., 2008), industry funding was
significantly associated with increased publication in our cohort. As registration has
become the norm, the non-publication of trial results may have become subject to greater
scrutiny. As a result, industry sponsors affiliated with London, Ontario may have started
encouraging their constituents to publish instead of withholding research. This could
include mandating better study planning and closer adherence to publication requirements
from ICMJE or other organizations, ultimately increasing the likelihood of publication.
Among our registered studies, drug studies made up the majority (Table 4) and seemed to
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be associated with a significantly greater likelihood of overall publication than other
types of interventional studies. However, this association was not significant for
publication with primary outcome, suggesting that there may be some risk of outcome
switching among drug studies. Similar to Rosenthal et al. (2015), we found signs that
surgical studies could be associated with a decrease in publication compared to nonsurgical studies, but our results were ultimately inconclusive. As with Rosenthal et al.
(2015), this may have been due to a lack of statistical power for surgical studies. Surgical
studies made up only 11% of our cohort (Table 4) and may also be decreasing in relative
frequency over time (Figure 10). Nevertheless, the consistency of our findings suggests
that surgical studies need to be studied further and with greater sample size. (Table 5)
Contrary to existing studies (Al-Durra et al., 2018; Khan et al., 2014), we found
prospective registration to be significantly associated with an increase in both overall
publication and publication with primary outcome, compared to retrospective registration
(Table 5). Likewise, each of our separately modeled outcome description criteria also
significantly increased publication, with some more than doubling the probability (Table
6). We found strong evidence of multicollinearity between these criteria (Table C5),
suggesting that studies that meet one criterion are likely to meet the others and that there
may be an underlying reason for this correlation. We speculate that prospective
registration and better-defined outcomes reflect overall better planning and critical
thinking prior to conducting the study. Not only do better outcome descriptions allow us
to better diagnose publication biases, it seems they also increase chances of successful
completion and eventual publication. This supports the need for more rigorous guidelines
for registry entries and protocols.
In line with existing research (Al-Durra et al., 2018; Blümle et al., 2014; Kasenda et al.,
2014; Pica & Bourgeois, 2016; von Elm et al., 2008), enrollment size was significantly
associated with an increase in both publication and publication with primary outcome,
with similar effect sizes for both (Table 7). For every 1000 additional study participants,
the incidence rate of publication increased by 1.4–1.5%. These findings suggest that
larger studies tend to have a greater likelihood of publication, which may reflect more
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available resources and personnel. Smaller studies may also lack statistical power,
leading to fewer significant results and lower rates of publication.

6.2 Time to Publication
Post-start time to publication in our cohort fell roughly in line with existing studies that
measured post-start or post-approval (Table 2, Table 3). However, the difference between
our median time to primary outcome completion and time to publication was fewer than
20 months (Table 3). This suggests a shorter post-completion time to publication than
existing studies, which reported time intervals up to twice as long (Table 2). Also, the
steep initial incline in cumulative incidence of publication (Figure 5) and strong evidence
of right-skew (Figure B3) suggest that most studies that publish tend to do so earlier.
Positive studies were generally published sooner than negative studies (Figure 5, Table
C13), reaffirming previous findings (Khan et al., 2014). In fact, positive results were
associated with a reduction in time to publication by almost a year. Favourable results
may motivate researchers to publish sooner, leading to further bias in the published
literature. Prospective registration was associated with a reduction in time to publication
of well over a year, which coincides with an increased likelihood of publication (Table
5). This may indicate better planning and foresight, leading to more efficient execution
and faster completion. In contrast to existing literature (Pica & Bourgeois, 2016),
industry funding was associated with a reduction in time to publication of over 2 years.
Our findings coincided with a greater rate of overall publication from industry funding
and an increase in industry-funded studies over time (Table 5, Figure 10), which could be
attributed to greater pressure from industry sponsors to register and publish. Considering
our median time to publication was roughly 4.5 years (Table 3), these study
characteristics combined could contribute to a total reduction of up to 90%. (Table 8)
Although drug studies were associated with an increase in publication (Table 5), it was
also associated with longer time to publication by almost a year. This suggests that drug
studies overall tend to take longer to complete and publish. It is also possible that nonindustry-funded and negative drug studies have a much harder time reaching publication
than their counterparts. Additionally, both randomized design and surgical studies failed
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to reach significance, suggesting that they do not have a substantial effect on time to
publication. However, for surgical studies, the lack of significance may have been due to
the lack of statistical power in our cohort (Table 4). (Table 8)

6.3 Publications Over Time
Both frequency and proportion of registered studies published seem to be steadily
increasing over time, particularly following FDAMA in 1997 (NLM, n.d.) (Figure 6,
Figure 7, Figure 8, Figure 9) and the ICMJE mandate in 2005 (De Angelis et al., 2004)
(Figure 7). The proportion of prospectively registered studies each year have also been
increasing since 2000 (Figure 10). This supports that the implementation of
ClinicalTrials.gov and ICMJE registration requirements have been beneficial towards
both increasing study registration and likelihood of publication. Although our graphs
showed a sudden decrease in publications in the most recent few years, this can easily be
explained by the increase in ongoing and completed studies that have simply not yet
reached publication (Figure 7, Figure 8). Adding an estimate of such studies produced a
more reasonable and consistent increasing trend (Figure 6). That being said, the observed
decrease suggests that 2.5 years was simply not enough time for all studies in our cohort
to reach publication. Nevertheless, these findings support a promising trend of increasing
publication rates over time, consistent with the findings of Khan et al. (2014). Notably,
frequency graphs seemed to be more effective at displaying sparse data than proportion
graphs, particularly with data prior to 1997 (Figure 6, Figure 7).
The reasons for the observed increases in annual proportion published are uncertain. On
the one hand, the increase has coincided with more prospective registration and a greater
proportion of RCTs, which suggest better accountability and quality of research. While
average sample sizes have somewhat decreased (Table B3), better methodology in recent
studies could have improved efficiency and reduced the size needed to achieve adequate
statistical power. On the other hand, the increased publication rate has also coincided
with an increase in proportion of industry-funded studies and a relative decrease in
surgical studies. This suggests that the increase in publication may instead be due to
greater industry pressure and an increase in types of studies that are more likely to
publish (Table 5). However, it should be noted that “industry-funded” includes studies
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that were also funded by other sources, which likely underrepresents the proportion of
academic and government-funded studies. It is also possible that some of the observed
increase in registered industry-funded studies is a result of increasing adoption of public
registries, in lieu of private industry registries, as opposed to a true increase in industryfunded research. (Figure 10)
Another noteworthy point is that the observed increase in total registered and
prospectively registered studies (Figure 7, Figure 10), particularly following the ICMJE
mandate in 2005 (De Angelis et al., 2004), suggests the possibility of some reverse
causation. For example, a strong pre-existing desire from researchers or industry sponsors
to publish may have pushed researchers to adhere to ICMJE publication policies, which
requires them to register before starting their trial. Although prospective registration may
be a predictive factor of publication (Table 5), the reverse relationship may be true where
studies are prospectively registered specifically because they already have a high
likelihood of publication success from other factors, such as high researcher motivation.
Our leaky bucket diagram (Figure 11) revealed that a study reaching completion and
publication were the biggest bottlenecks in the research process. The vast majority of
registered studies are started in some capacity but meet resistance either while conducting
the study or submitting the results for publication. The last stage, while not the steepest
relative drop, suggests that a troubling one in five published studies do not include their
planned primary outcome at all.
The findings from our icon array diagram (Figure 12) were also troubling. While the vast
majority of registered and completed studies were potentially negative, positive studies
made up the majority of published studies. These findings support that positive studies
are highly overrepresented in the published literature. Furthermore, there are noticeably
fewer completed studies with positive results than published studies. This mismatch is
possible because ongoing and stopped studies may still publish results. However, this
could be indicative of selective outcome reporting because these studies would
presumably be publishing before they finished ascertaining all their planned outcomes.
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6.4 Implications for London, Ontario
It seems that research institutions affiliated with London, Ontario are headed in the right
direction, as rates of prospective registration are increasing (Figure 10). Excluding the
most recent years, annual publication rates also seem to be increasing at a steady pace
(Figure 7). This could be due to increasing awareness of publication bias and better local
research policies, including the introduction of registration requirements for ethics
approval of human clinical trials at Western University (OHRE, 2016). Furthermore,
studies that do publish generally do so sooner than contemporary estimates from other
studies on time to publication (Table 2, Table 3). If these trends continue, research loss
could be better mitigated in the future.
Unfortunately, the rate of failure to publish remains high for studies associated with
London, Ontario over the past two decades. Compared to other studies on nonpublication, our requirements for identifying acceptable corresponding publications were
exceptionally lenient, essentially only requiring matching NCT numbers and some form
of results. Even regarding whether publications included their planned primary outcome,
we only required that it reasonably matched one of their published outcomes. We did not
scrutinize changes in secondary outcomes, analysis plans, measurement timepoints, or
other issues like interpretive bias (spin) (Chiu et al., 2017). Despite this leniency, our
proportion published ranks as one of the lowest among existing studies (Table 1). In fact,
our estimated 30–38% rate of publication is lower than any of the studies that focussed
on select regions and institutions, which generally reported rates of 50% or more (Blümle
et al., 2008, 2014; Kasenda et al., 2014; Kirkham et al., 2016; Menzel et al., 2007;
Rosenthal et al., 2015; von Elm et al., 2008). While one could argue that our use of
ClinicalTrials.gov did not adequately restrict our data to institutions based in London,
Ontario, our findings are no less troubling for the region as a whole.
The increase in absolute number of registered studies and publications over time, while
the overall rate of failure to publish remains high, could be due to increases in industryfunded studies (Figure 10), which may be more likely to publish and sooner (Table 5,
Table 8). Further research is necessary to explore the barriers that academic and
government-funded studies may face when reaching publication. Otherwise, the
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published literature could become increasingly dominated by industry studies. Notably,
the research affiliated with London, Ontario is already dominated by positive studies and
drug studies (Figure 10, Figure 12). If researchers are reluctant to conduct or submit
studies with anticipated low publication success, this would further bias the available data
and be detrimental to evidence-based decision-making. In addition, an increase in overall
publications does not necessarily mean a decrease in data loss. Our findings have shown
that outcome switching is prevalent among studies affiliated with London, Ontario and
can significantly impact measures of publication (Table 4). It is possible that the increase
in publications may have coincided with an increase in selective outcome reporting.
Even if studies are legally required to submit their results to the FDA, many still fail to do
so (Prayle et al., 2012) and this does not prevent discrepancies in outcome reporting
(Thaler et al., 2015). Publication of results is largely voluntary and inconsistent at best,
especially among studies lacking external pressure from industry sponsors. Unpublished
data is not easily accessible to the public and will have limited impact. In the absence of
regulatory pressure, the majority of London, Ontario research is likely still being wasted.
Thus, it is clear that more improvements are necessary to the current research
infrastructure in London, Ontario.

6.5 Limitations and Future Directions
A major limitation of our study was our data source. Some of the metadata on
ClinicalTrials.gov may not have been reliable, especially since we accepted estimated
values. For example, some studies had time to completion intervals of zero months
(Table 3), which seems highly implausible and suggests the registry dates were incorrect.
We did not include observational or qualitative studies in our cohort, which may have
yielded different results from interventional studies. We also accepted studies that had
any affiliation with London, Ontario instead of restricting to institutions based in the city.
While this likely makes our data more representative of all research conducted in
London, Ontario, it means that our results may include multicenter studies influenced by
factors outside of the region. A potential solution could be to use a local registry instead,
such as ethics review submissions. This could provide more accurate metadata, include
non-clinical studies, and limit the regional scope more effectively. R scripts may also be
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used to organize large sets of registry metadata further (Ramagopalan et al., 2014),
instead of relying solely on the registry’s existing filter functions.
Both our search for planned studies and corresponding publications were limited to
publicly accessible databases, as we believed these to be representative of most clinical
research. We did not reach out to the authors themselves for their manuscripts or
publications, which would likely have increased our publication estimates. Additionally,
more recently registered studies in our cohort may not have had adequate time to
complete their studies and submit publications, leading to right censoring where
publications from studies that are slower to publish may not have been detected within
our search window. This could be mitigated by increasing the duration of follow-up and
searching for publications at a later date. Our study also did not include grey literature,
such as clinical study reports and registry results. Consequently, we were unable to
compare the characteristics of published and unpublished literature, including whether
favourability of study results could be associated with likelihood of publication. This also
prevented us from accurately representing the distribution of positive and negative results
among registered and completed studies (Figure 12). Future endeavours may include
using grey literature sources and searching for trial results on ClinicalTrials.gov.
Another issue is that our search strategy for published literature relied heavily on
publications including their trial NCT number, as authors may neglect to include it. A
more comprehensive approach may entail searching other metadata entries, such as title
and treatment, when the NCT number alone fails to find a corresponding publication.
Furthermore, our screening of publications was mostly limited to study abstracts, which
may not adequately represent all the published outcomes. For example, authors may
choose to include some results in their appendices, which we would have missed.
We adopted a relatively simple approach in our analysis for the purposes of exploration.
Most of our data interpretation assumed a linear and sequential progression through the
research process. We assumed the registry and publication dates would represent
common stages of the research process, but the amount of work done at any given stage
may vary drastically from study to study. Our log-binomial and linear regression analysis
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also did not account for right censoring, which could reduce the validity of our estimates.
Future endeavours may include expanding on our time-to-event analysis, which may be
better suited to the limitations of our data and allow us to better understand the influences
of study characteristics on likelihood of publications over time. Potential models include
the parametric Weibull regression, which would not require strong adherence to
assumptions of temporality, censoring, or proportional hazards.
We did not assess outcome reporting bias in-depth. Further analysis of selective outcome
reporting could give us a better understanding of data loss among published studies. For
example, industry funding may increase likelihood of overall publication but have the
opposite effect on publishing individual outcomes (Kirkham et al., 2016). Although
harder to detect, selective outcome reporting and its causes are no less important and may
warrant its own study. Additionally, although we assessed the associations of drug and
surgical studies, the reasons for their differences in likelihood of publication are not clear.
For example, different types of treatments may be subject to different thresholds for
favourable results or adverse effects. To that end, a greater or targeted sample may be
beneficial, as our cohort lacked statistical power for surgical studies. With regard to our
analysis of registry outcome description quality, we did not consider the recent changes
made to the ClinicalTrials.gov registration requirements in 2017, which now require
much greater specificity in registered outcomes (i.e., specific metric, measurement,
timepoint, etc.) (Collins & Burwell, 2016). Further research is necessary to assess the
effectiveness of these updated requirements and their influence on publication.
While most of our graphs proved effective at visually conveying information, there were
some areas that could be improved. Our proportion published over time graphs could
include more landmark timepoints, such as local policy changes. Our leaky bucket and
icon array diagrams could also be expanded to include more stages of the research
process, such as obtaining funding, completing analysis, and journal submission.
Lastly, our study only covered a small portion of the research process: publication. We
did not attempt to address issues in study design, data collection, analysis, or
interpretation. Lack of bias prevention, poor quality data, and manipulation of statistics to
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reach significance (p-hacking) may diminish the integrity and reproducibility of research
(Munafò et al., 2017). With regard to our registry data collection, we only used the most
recent information and did not consider potential changes over the course of the study.
For example, researchers may have changed their hypotheses and outcomes after
completing analysis to make their results appear more favourable (HARKing) (Munafò et
al., 2017). Post hoc changes to registry data may bias results and threaten the reliability of
registries as data sources. Thus, more in-depth research into other aspects of the research
process is necessary to improve research transparency and inform better practises.

6.6 Conclusion
Publication bias is a widespread issue and London, Ontario is no exception. As many as
two-thirds of registered studies fail to publish their results. While our cohort had lower
publication rates than contemporary studies, those that did publish generally did so
sooner. Prospective study registration and industry funding were associated with both a
significantly increased likelihood of publication and shortened post-start time to
publication. Randomized design, larger enrollment sizes, and better outcome planning
were associated with increased likelihood of publication, while positive results were
associated with shortened time to publication. Drug studies were more likely to publish
but tended to take longer than non-drug studies.
Our incorporation of visual diagrams proved to enhance the understandability of our data
and outlined details that may not have been obvious from the statistics alone. The
observed increase in publications in London, Ontario seems to coincide with increased
prevalence of randomized, prospectively registered, and industry-funded studies. These
types of studies were also more likely to be published, suggesting that the increase in
publication rate may be due to a shift in the distribution of study types as opposed to a
general increase in all research. Furthermore, many bottlenecks remain in the research
process and positive results are still disproportionately represented in the published
literature. These findings bring us closer to understanding the factors that influence
publication rates and are potential avenues for addressing publication bias.
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Evidence suggests that preventing non-publication and encouraging timeliness of
publication should start even before studies are conducted, as many potentially predictive
factors exist as early as study registration. We believe that rigorous guidelines need to be
developed and enforced for registry entries and study protocols. Requiring better
planning and documentation, in addition to prospective registration, may increase the
likelihood of publication and allow for greater transparency in research methodology.
Pre-study sample size calculations could also help to prevent underpowered studies.
Greater effort is still necessary to explore and address barriers to different types of
interventional studies that may have lower publication rates. New policies could be
introduced in London, Ontario that require certain types of studies (i.e., non-industry,
surgical, etc.) to submit or publish their results within a set timeframe, introducing greater
regulatory pressure. This would ensure that clinical studies of all types may reach
publication in a timely manner. Another approach to decreasing research waste may
instead be increasing the accessibility of unpublished research. Opening up industry
registries and simplifying clinical study reports can greatly increase their usage as sources
of information. In addition, more consistent reporting in public registries like
ClinicalTrials.gov, coupled with greater pressure to submit study results, may pave the
way for innovations in automated tools. For example, a system could be developed to
automatically produce a meta-analysis of relevant registry outcome data based on a string
of parameters, such as intervention and outcome. This would remove several barriers to
accessing unpublished data and greatly reduce the need for formal publications.
Although awareness of publication bias is increasing, it is clearly still a prevalent issue.
Our findings have produced new insights on the influences of publication, as well as time
to publication, that may inform additional measures for increasing publication rates. Not
only would addressing publication bias improve the overall quality of clinical research,
but it would also reduce bias in the published literature and increase access to important
data for clinical decision-making. As a result, we could ultimately prevent research loss,
wasted resources, and further patient harm. We hope that our work here can serve as a
foundation for future research and a template for other regions or institutions to follow.
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Appendices
Appendix A: Literature Review Systematic Search Strategy and Results
Key search terms: publication bias, outcome reporting bias, registries, ethics submissions,
protocols, RCTs
MEDLINE search strategy:
1. Exp Publication Bias/
2. (publication bias or unreport* or incomplete report* or “not reported” or outcome
omission or partial report* or outcome suppress* or non*publication or report*
bias).ti,ab,tw.
3. 1 or 2
4. Exp Registries/
5. (register* protocol or register* trial or register* study or register* method or trial
register* or ethics submission* or ethics approval or ethics application*).ti,ab,tw.
6. 4 or 5
7. Exp Clinical Protocols/
8. Protocol$.ti,ab,tw.
9. 7 or 8
10. Exp Randomized Controlled Trials as Topic/
11. (RCT or randomi#ed controlled trial*).ti,ab,tw.
12. 10 or 11
13. 6 or 9
14. 3 and 12 and 13
EMBASE search strategy:
1. Exp publishing/
2. (publication bias or unreport* or incomplete report* or “not reported” or outcome
omission or partial report* or outcome suppress* or non*publication or report*
bias).ti,ab,tw.
3. 1 or 2
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4. Exp register/
5. (register* protocol or register* trial or register* study or register* method or trial
register* or ethics submission* or ethics approval or ethics application*).ti,ab,tw.
6. 4 or 5
7. Exp clinical protocol/
8. Protocol$.ti,ab,tw.
9. 7 or 8
10. Exp “randomized controlled trial (topic)”/
11. (RCT or randomi#ed controlled trial*).ti,ab,tw.
12. 10 or 11
13. 6 or 9
14. 3 and 12 and 13
Ovid search of MEDLINE (n = 475) and EMBASE (n = 714) – Oct. 16, 2019
Total results after removing duplicates: 1007
Level 1 Exclusion: 842
Level 1 Inclusion: 165 + 20 additional papers found
Level 2 Exclusion: 170
Level 2 Inclusion: 15 primary studies on RCTs – Dec. 14, 2019
165 of 1007 results from the systematic search were included for final screening, with 20
additional papers found from manual and forward/backward citation searching. A total of
15 relevant primary studies were included.
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Appendix B: Supplementary Data and Calculations for Descriptive Statistics
Table B1
Paired t-test between study publication with any results and publication with primary
outcome (p < 0.001)
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Table B2
Exact McNemar's Chi2 test between study publication with any results and publication
with primary outcome (p < 0.001)

Both paired t-test (Table B1) and McNemar's Chi2 test (Table B2) showed a statistically
significant difference between the publication outcome measures (both with p < 0.001).
The McNemar’s Chi2 test should be robust to structural zeros due to its paired nature, our
use of the exact form, and our large sample size.
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Figure B1. Histogram of time to primary outcome variable.

Figure B2. Histogram of time to overall completion variable.
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Figure B3. Histogram of time to publication variable.
Histograms for time to primary outcome (Figure B1), time to overall completion (Figure
B2), and time to publication (Figure B3) demonstrated clear right skew.
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Figure B4. Histogram of entire enrollment size variable.

Figure B5. Histogram of enrollment size variable up to 5000.
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Due to the extreme range of enrollment sizes (Figure B4), a truncated version was
generated to provide a clearer view (Figure B5). Both demonstrated a clear right skew.
Table B3
Annual average enrollment sizes of registered studies with randomized versus nonrandomized design or either, by year of first participant enrolled
Mean Enrollment Size
Year

Randomized

Non-Randomized

Either

Design

Design

1983

1441

-

1441

1988

-

573

573

1989

154

-

154

1992

9000

-

9000

1993

953

10

639

1994

2000

-

2000

1995

1302

1534

1354

1996

314

-

314

1997

4455

151

2542

1998

1426

201

1108

1999

496

324

460

2000

1234

124

852

2001

842

6356

1629

78

2002

602

116

505

2003

1441

912

1399

2004

542

627

550

2005

627

364

613

2006

1103

668

1053

2007

822

255

745

2008

962

254

851

2009

857

195

736

2010

1372

441

1217

2011

1921

257

1617

2012

530

211

477

2013

1361

246

1191

2014

1142

515

1022

2015

769

229

666

2016

1111

187

957

2017

1676

284

1484

Overall

1088

394

980
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Appendix C: Supplementary Data and Calculations for Comparative Analysis
Table C1
Pairwise Pearson’s coefficient between study publication and enrollment size (p < 0.05)

Table C2
Point-biserial correlation for binary publication variable and enrollment size (p < 0.001)

Both Pearson coefficient (Table C1) and point-biserial correlation (Table C2) showed a
statistically significant positive correlation (p < 0.05 and p < 0.001, respectively) between
publication and enrollment size.
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Table C3
Multivariable log-binomial regression model for association between study
characteristics (randomized design, prospective registration, industry funding, surgical
study, and drug study) and study publication
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Table C4
Multivariable log-binomial regression model for association between study
characteristics (randomized design, prospective registration, industry funding, surgical
study, and drug study) and study publication with primary outcome

Log-binomial regression models for publication (Table C3) and publication with primary
outcome (Table C4) did not show evidence of multicollinearity (VIF < 10).
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Table C5
Variance inflation factors of log-binomial regression covariates (randomized design,
prospective registration, industry funding, surgical study, and drug study), for
association with study publication, including all outcome description criteria (metric,
measurement, and timepoint)
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Table C6
Variance inflation factors of log-binomial regression covariates (randomized design,
prospective registration, industry funding, surgical study, and drug study), for
association with study publication, including one outcome description criterion (metric)
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Including all outcome description criteria as covariates in the same regression model
showed strong evidence of multicollinearity (Table C5). Therefore, each criterion was
modeled individually for publication and publication with primary outcome, which
reduced multicollinearity to acceptable levels in every case (VIF < 10). Output and
variance inflation factors for an example model, including only one of the criteria
variables (mention of metric), are given above (Table C6).
Table C7
Multivariable modified Poisson regression model for association between study
characteristics (enrollment size, randomized design, prospective registration, industry
funding, surgical study, and drug study) and study publication
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Table C8
Multivariable modified Poisson regression model for association between study
characteristics (enrollment size, randomized design, prospective registration, industry
funding, surgical study, and drug study) and study publication with primary outcome
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Table C9
Multivariable negative binomial regression, including likelihood ratio test with Poisson
regression (p > 0.05), for association between study characteristics (enrollment size,
randomized design, prospective registration, industry funding, surgical study, and drug
study) and study publication
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Table C10
Multivariable negative binomial regression, including likelihood ratio test with Poisson
regression (p > 0.05), for association between study characteristics (enrollment size,
randomized design, prospective registration, industry funding, surgical study, and drug
study) and study publication with primary outcome

Likelihood ratio tests were statistically non-significant and did not suggest negative
binomial regression better fit the data (both p > 0.05), demonstrating lack of evidence for
overdispersion (Table C9, Table C10). Therefore, Poisson regression was adequate
(Table C7, Table C8).
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Figure C1. Residual and density plots of multiple linear regression for association
between study characteristics and time to publication.
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Figure C2. Residual and density plots of multiple linear regression for association
between study characteristics and log-transformed time to publication.
Multiple linear regression model for effects of covariates on time to publication failed to
meet assumptions of normality and homoskedasticity. The residual plot, boxplot, kernel
density curve, and Q-Q plot for time to publication showed strong evidence of right skew
(Figure C1). Therefore, log transformation of the time to publication variable was
necessary, which improved its normality (Figure C2).
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Figure C3. Residual versus fitted outcome plot for log-transformed time to publication in
multiple linear regression model.
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Table C11
Additional heteroskedasticity tests for log-transformed time to publication multiple linear
regression model (both p > 0.05)

Although the tests for constant variance were inconclusive (Table C11), the residual
versus fitted outcome plot (Figure C3) showed some evidence of heteroskedasticity.
Therefore, a robust variance parameter was used in the linear regression model (Table
C12).
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Figure C4. Component plus residual plots for predictors of log-transformed time to
publication multiple linear regression model.
Due to the dichotomous nature of the covariates in the linear regression model, the
predictor-outcome relationships were linear (Figure C4) and inherently met the
assumptions of linearity.
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Table C12
Analogous structural equation function of multiple linear regression model for
association between study characteristics (positive results, randomized design,
prospective registration, industry funding, surgical study, and drug study) and logtransformed time to publication, using robust variance
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Table C13
Log-rank test to compare survival to publication of positive versus negative studies (p <
0.05)

Log-rank test showed statistically significant difference between survival distributions of
positive and negative studies for reaching publication (p < 0.05) (Table C13).
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Table C14
Schoenfeld residuals test for proportional hazards assumption of multivariable Cox
regression for association between study characteristics (positive results, randomized
design, prospective registration, industry funding, surgical study, and drug study) and
survival to publication (p < 0.05)
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Figure C5. Log-log plot for “survival” to publication of positive (green dashed line)
versus negative (red solid line) studies, adjusting for randomized design, prospective
registration, industry funding, surgical study, and drug study.
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Table C15
Multivariable Weibull regression for association between study characteristics (positive
results, randomized design, prospective registration, industry funding, surgical study,
and drug study) and survival to publication

As the Schoenfeld residuals test was statistically significant (p < 0.05) (Table C14) and
the log-log plot showed the positive and negative study survival functions were not
parallel (lines crossed) (Figure C5), there is evidence that our data does not meet the
proportional hazards assumption. Therefore, a parametric model such as Weibull
regression should be used instead (Table C15).
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Appendix D: Supplementary Data and Calculations for Graphics
Table D1
Percentage and frequency of registered studies in each status category
Study Status

Percentage (%)

Frequency (N = 2446)

Completed

66.43

1625

Active, not recruiting

10.47

256

Enrolling by invitation

0.25

6

Recruiting

6.58

161

Terminated

10.83

265

Suspended

0.16

4

Unknown status

4.50

110

Withdrawn

0.78

19

Cumulative Total

100

2446

Table D2
Annual frequencies of study publication and simplified status, by year of first participant
enrolled
Year

Published

Unpublished

Completed

Ongoing

Stopped

1983

1

0

0

0

0

1988

1

0

0

0

0

1989

1

0

0

0

0
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1992

0

1

1

0

0

1993

2

1

1

0

0

1994

3

3

3

0

0

1995

3

6

6

0

0

1996

1

4

4

0

0

1997

2

10

10

0

0

1998

7

22

18

1

3

1999

6

22

21

1

0

2000

9

29

26

2

1

2001

11

29

28

0

1

2002

13

47

38

1

8

2003

29

52

47

0

5

2004

27

65

57

1

7

2005

44

88

67

2

19

2006

61

96

71

0

25

2007

51

98

69

3

26

2008

73

68

51

4

13

2009

70

67

44

4

19

2010

61

83

54

8

21

100

2011

787

75

49

11

15

2012

76

100

67

12

21

2013

75

83

48

10

25

2014

71

86

36

32

18

2015

67

106

54

29

23

2016

44

130

41

64

25

2017

38

150

33

87

30

Note. “Unpublished” is the sum of completed, ongoing, and stopped studies for each
year.
Table D3
Annual actual and estimated percentages of studies that are or will be published, by year
of first participant enrolled
Year

Actual Published

Estimated Total

Not Yet Published

(%)

Published (%)

(%)

1983

100

100

0

1988

100

100

0

1989

100

100

0

1992

0

0

0

1993

66.67

66.67

0

1994

50

50

0

1995

33.33

33.33

0
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1996

20

20.02

0.02

1997

16.67

16.70

0.04

1998

24.14

24.22

0.08

1999

21.43

21.55

0.12

2000

23.68

23.84

0.15

2001

27.50

27.68

0.18

2002

21.67

21.88

0.21

2003

35.80

36.31

0.51

2004

29.35

29.93

0.58

2005

33.33

34.15

0.81

2006

38.85

39.93

1.08

2007

34.23

35.45

1.23

2008

51.77

54.24

2.46

2009

51.09

54.26

3.17

2010

42.36

45.67

3.31

2011

50.98

56.41

5.43

2012

43.18

49.56

6.38

2013

47.47

57.10

9.63

2014

45.22

58.51

13.28
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2015

38.73

57.78

19.05

2016

25.29

48.53

23.24

2017

20.21

58.06

37.85

Sample estimation for number of studies not yet published from 2016 (Table D3):
From Table D2, we see that 44 out of 174 studies (25.29%) started in year 2016 have
already been published. Length of time from beginning of 2016 to end of July 2020 is
then calculated in months as follows:
(2017 – 2016) × 12 + 43 = 55 months

Using Stata, we determine 55 months to be roughly the 52.11th percentile of the time to
publication variable distribution. This means the proportion of studies published since
2016 is estimated to represent only 52.11% of all studies that will be published from that
year. Thus, we divide the actual proportion published by the percentile number (as a
proportion) to get the estimated total proportion of studies that have and will be published
given time:
0.2529/0.5211 = 0.4853
We then find the difference between the estimated and actual proportion to get the
estimated proportion of not yet published studies:
0.4853 – 0.2529 = 0.2324 = 23.24%
Table D4
Chi2 test of independence between study publication and year of first participant
enrolled, from 1997 onwards (p < 0.001)
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Table D5
One-way ANOVA between study publication and year of first participant enrolled, from
1997 onwards (p < 0.001)

Both the Chi2 test of independence (Table D4) and one-way ANOVA (Table D5) showed
a statistically significant relationship between study publication and start year (both p <
0.001). Both tests were restricted to 1997 and onwards due to sparsity of preceding data
(Table D2), which also coincides with the year ClinicalTrials.gov was formalized.
Table D6
Characteristics of registered studies, by year of first participant enrolled (annual)
Year

Registered

Randomized

Industry

Surgical

Drug

Studies

Design (%)

Funding (%)

Study (%)

Study (%)

1983

1

100

0

0

0

1988

1

0

0

100

100

1989

1

100

100

0

100

1992

1

100

0

100

0

1993

3

66.67

0

0

66.67

1994

6

100

16.67

0

83.33
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1995

9

77.78

22.22

44.44

77.78

1996

5

100

0

40

40

1997

12

50

0

41.67

83.33

1998

29

72.41

31.03

24.14

72.41

1999

28

82.14

17.86

39.29

67.86

2000

38

63.16

31.58

15.79

84.21

2001

40

80

50

22.50

90

2002

60

75

53.33

8.33

86.67

2003

81

87.65

70.37

14.81

80.25

2004

92

89.13

70.65

10.87

78.26

2005

132

93.94

75

8.33

83.33

2006

157

88.54

70.06

8.28

80.25

2007

149

86.58

69.13

11.41

73.83

2008

141

84.40

78.01

7.09

78.01

2009

137

81.75

72.26

8.03

72.99

2010

144

83.33

70.83

9.03

77.78

2011

153

81.70

65.36

9.80

65.36

2012

176

83.52

64.20

10.80

65.34

2013

158

84.81

65.19

9.49

68.35
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2014

157

80.89

62.42

12.74

63.69

2015

173

80.92

64.16

7.51

63.58

2016

174

83.33

60.34

5.17

60.92

2017

188

86.17

57.45

10.64

63.83

Overall

2446

83.81

63.98

10.59

71.63

Table D7
Percentage of studies that progressed to each stage of the research process
Stage

Percentage of Total

Percentage of Previous

Registered Studies (%)

Stage (%)

100

-

Started

94.72

94.72

Completed

66.43

70.13

Published

37.82

56.93

Published with Primary

30.38

80.32

Registered

106

Table D8
Frequency and percentage of positive and negative studies across relevant stages of the
research process
Stage

Positive

Negative

Unpublished

Total

Percentage

Results

Results

Registered

782

143

1521

2446

31.97

Completed

574

107

944

1625

35.32

Published

782

143

-

925

84.54

Published

616

127

-

743

82.91

Positive (%)

with Primary
Note. The “started” stage was not included due to redundancy with “registered”.
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